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ABSTRACT

Advancements in prognostication have improved the subdivision of chronic
lymphocytic leukaemia (CLL) into diverse prognostic subgroups. In CLL, IGHV
unmutated and IGHV3-21 genes are associated with a poor-prognosis, conversely,
IGHV mutated genes with a favourable outcome. The finding of multiple CLL
subsets expressing ‘stereotyped’ B-cell receptors (BCRs) has suggested a role for
antigen(s) in leukemogenesis. Patients belonging to certain stereotyped subsets share
clinical and biological characteristics, yet limited knowledge exists regarding the
genetic and epigenetic events that may influence their clinical behaviour. This thesis
aimed to, further investigate Swedish IGHV3-21-utilising patients, screen for genetic
and DNA methylation events in CLL subgroups/subsets and study DNA methylation
over time and within different CLL compartments.
In paper I, IGHV gene sequencing of 337 CLL patients from a Swedish
population-based cohort revealed a lower (6.5%) IGHV3-21 frequency relative to
previous Swedish hospital-based studies (10.1-12.7%). Interestingly, this frequency
remained higher compared to other Western CLL (2.6-4.1%) hospital-based cohorts.
Furthermore, we confirmed the poor-outcome for IGHV3-21 patients to be
independent of mutational and stereotypy status.
In paper II, genomic events in stereotyped IGHV3-21-subset #2, IGHV4-34subset #4 and subset #16 and their non-stereotyped counterparts were investigated via
SNP arrays (n=101). Subset #2 and non-subset #2 carried a higher frequency of
IV

events compared to subset #4. A high frequency of del(11q) was evident in IGHV321 patients particularly subset #2 cases, which may partially explain their poorprognosis. In contrast, the lower prevalence of aberrations and absence of poorprognostic alterations may reflect the inherent low-proliferative disease seen in subset
#4 cases.
In papers III and IV, differential methylation profiles in IGHV mutated and
IGHV unmutated patients were identified using DNA-methylation microarrays. CLL
prognostic genes (CLLU1, LPL), tumor-suppressor genes (TSGs) (ABI3, WISP3) and
genes belonging to TGF-ß and NFkB/ TNFR1 pathways were differentially
methylated between the subgroups. Additionally, the re-expression of methylated
TSGs by use of methyl and deacetyl inhibitors was demonstrated. Interestingly,
analysis of patient-paired diagnostic/follow-up samples and patient-matched lymph
node (LN) and peripheral blood (PB) cases revealed global DNA methylation to be
relatively stable over time and remarkably similar within the different compartments.
Altogether, this thesis provides insight into the aberrant genomic and DNA
methylation events in divergent CLL subgroups. Moreover this thesis helps
distinguish the extent to which DNA methylation changes with respect to time and
microenvironment in CLL.

V

DECLARATION

I certify that this thesis which I now submit for examination for the award of PhD, is
entirely my own work and has not been taken from the work of others, save and to the
extent that such work has been cited and acknowledged within the text of my work.

This thesis was prepared according to the regulations for postgraduate study by
research of the Dublin Institute of Technology and has not been submitted in whole
or in part for another award in any other third level institution.

The work reported on in this thesis conforms to the principles and requirements of the
DIT's guidelines for ethics in research.

DIT has permission to keep, lend or copy this thesis in whole or in part, on condition
that any such use of the material of the thesis be acknowledged.

Signature

Date

VI

ACKNOWLEDGEMENTS

This work was carried out at the Department of Immunology Genetics and Pathology,
Rudbeck Laboratory, Uppsala University in association with the School of Biological
Sciences, Dublin Institute of Technology, Ireland. Financial support was provided by
the Nordic Cancer Union, the Swedish Cancer Society, the Swedish Medical Council
and ABBEST Ireland.
First of all I would like to sincerely thank my supervisors Dr. Fergus Ryan and Prof
Richard Rosenquist. Thanks for taking a chance on me and for giving me the
opportunity undertake such rewarding projects.
Thank you to my most recent co-supervisor Larry Mansouri. You have always
encouraged me whenever I needed it. Thanks for all the assistance, words of advice
and suggestions I really appreciate it!
To my lab lads and lassies, both past and present, Meena, thanks for allowing me to
collaborate with you at the start of my studies, I will never forget our most interesting
discussions!!!. Fiona, thanks for keeping me going, making me laugh albeit
sometimes at my own expense!! You’re all right for a south-sider! Maria! Spiggelty
wiggelty!!! Thanks for taking an interest in using Irish slang you are only ‘savage’ at
it now! Marie, thanks for your good humour and sound advice!!! Rebeqa! I really
enjoyed working with you on the SNP Paper, thank you for keeping me focused!
Lesley! Thanks for everything!! You truly are a great friend and a great agony aunt!!.
VII

Thanks for taking me in when I first came to Uppsala and keeping me forever
entertained. Mi, thanks a million for all the fun times and laughs!! To Arifin, Ja,
Ingrid, Anna, Djana, Cecilia and Andreas thanks for making the lab such a great place
to work.
I would also like to thank Christer Sundstrom for all his help in finding samples and
for “donating” the occasional few millilitres of blood!!! Special thanks to our
Swedish collaborators Lotta Bergh and Anders Rosen!! Thanks to our other European
colloborators. Kostas Stamatopolous, Fred Davi, Christian Geisler and Gunnar
Juliusson for all their contributions! Sincere thanks to Hanna Göransson Kultima and
Isaksson for all their hard bio-informatic work.

To all the Rudbeck/Akademiska/Ångstrom/BMC gang!! Where do I start…. you
know who all you trouble makers are….but just in case others don’t know, I feel its
my duty to warn them…Jelena, Lucy, Johan S, Chris, Johan K, Sara K, Jess, Ammar,
Paul, Demet, and Daniel and Tatjana. Thanks for keeping me sane!!!! More
importantly thanks for making my 4 years here enjoyable. I will miss all the parties,
laughs and friendship!
To Antonia, Charlotte, Prasoon, Lotta S, Pernilla, Helena JW, Fredrik Ö, Chandra’s
army- (Tanmoy, Deb, Matthieu, Sanhita Gaurav), Tobias B, Grzegorz, Viktoria A
Spyros, Xiang, Umash, Jimmy, Sara L,Yanara, Lothar, Marie H, Sonia, the dutch
dudes, Eva H, Annika H, the genome centre girlies, the teaching crew-Viktoria,
Angie, Madhu, Rachel, Lena Å and Hamid … big thanks for making Rudbeck a cool
place to work!!!
VIII

I would like to thank Joe Vaughan, Brid Ann Ryan and Paddy Mc Hale (DIT) for
helping me and encouraging me over my undergraduate and post graduate years!
Also thank you to Joanne Richards of Baylor college of Medicine.
To my Irish mates, Dave, Eileen, Sarah, Gav, Lynne, Cliona and Fats!! Thanks for
coming over to visit me and staying friends with the NERD!!!
Big thanks to all my Swedish buddies!!!
To my Swedish family the ‘‘Janssons’’. Thanks for taking me in as one of your own.
You have truly looked after me!!! Special thanks to pappa. Tack för alla sms.!!!
To my family, thanks for always being there and never doubting me! Thanks for your
never ending support even if you still don’t understand what exactly what I have been
doing over here!!!.......... NO… dad I am not still writing my essay for school… this
is it… what you think?’’
Last but by no means least…Mattias! I know I might regret putting this in
writing…but you have the patience of a saint. I can simply say that without you I
wouldn’t have made it.!! Thanks for everything xxx

IX

ABBREVIATIONS

5’aza
ABI3
aCGH
ADORA3
AID
AKT
AML
AMP
ANGPT2
ATM
BAC
BCL10
BCL2
BCR
BMSCs
C
CARD15
CCL22
CD
CD40L
CDK
CDR
CGH
CHARM
CLL
CLLU1
CMV
CNA
CNAT
CNN-LOH
CNV
CpG
CXCR4
D
DAC
DAPK1
ddNTPs
DLEU7
DLEU1
DNA
DNA-PK
DNMT

5-azacytidine
ABI family member 3
Array comparative genomic hybridisation
Adenosine A3 receptor
Activation induced deaminase
V-akt murine thymoma viral oncogene homolog
Acute myeloid leukaemia
Adenosine monophosphate
Angiopoietin 2
Ataxia telangiectasia mutated
Bacterial artificial chromosome
B-cell CLL/lymphoma 10
B-cell CLL/lymphoma 2
B cell receptor
Bone marrow stromal cells
Constant
Caspase recruitment domain family, member 15
C-C motif chemokine 22
Cluster of differentiation
CD40 ligand
Cyclin dependent kinase
Complementarity determining region
Comparative genomic hybridization
Comprehensive high-throughput arrays for
relative methylation
Chronic lymphocytic leukaemia
Chronic lymphocytic leukaemia up-regulated gene 1
Cytomegalovirus
Copy number alteration
Copy number analysis tool
Copy number neutral loss of heterozygosity
Copy number variation
Cytosine-phosphate-guanine
C-X-C chemokine receptor 4
Diversity
5-aza 2’-deoxycytidine
Death-associated protein kinase 1
Dideoxy nucleotide triphosphates
Deleted in lymphocytic leukaemia 7
Deleted in lymphocytic leukaemia 1
Deoxyribonucleic acid
DNA dependent protein kinase
DNA methyltransferase
X

DNMT3B
DNMT3L
EBV
ERK
ESCs
EXO
EZH2
FAS
FISH
FOXE1
FWR
GC
GLRB
GRM7
H3K27
H3K4
H3K9
HELP
HIP1R
HPLC
IBTK
IG
IGH
IGHD
IGHJ
IGHV
IGK
IGL
IL17RC
IL2
IPF1
IWCLL
J
JAIRD2
LC
LEF1
LINES
LMO2
LN
LPL
LPS
MAPK
MBD2
MBL
Mbp
MCL-1
MDM2

DNA methyltransferase 3
DNA methyltransferase 3 ligand
Epstein Barr virus
Extracellular signal related kinase
Embryonic stem cells
Exonuclease
Enhancer of zeste homolog 2
TNF receptor superfamily, member 6
Flourescent in-situ hybridisation
Forkhead Box E1
Framework region
Germinal center
Glycine receptor Beta
Glutamate receptor metabotropic 7
Histone 3 lysine 27
Histone 3 lysine 4
Histone 3 lysine 9
HpaII tiny fragment Enrichment by Ligationmediated PCR
Huntingtin interacting protein 1 related
High pressure liquid chromatography
Inhibitor of Bruton agammaglobulinemia tyrosine
kinase
Immunoglobulin
Immunoglobulin heavy
Immunoglobulin heavy diversity
Immunoglobulin heavy joining
Immunoglobulin heavy variable
Immunoglobulin kappa
Immunoglobulin lambda
Interleukin 17 receptor C
Interleukin 2
Pancreatic and duodenal homeobox 1
International workshop of chronic lymphocytic
leukaemia
Joining
Jumonji- and ARID-domain-containing protein
Light chain
Lymphoid enhancer binding factor 1
Long Interspersed Nuclear Elements
LIM domain only 2
Lymph node
Lipoprotein lipase
Lipo-polysaccharide
Mitogen activated protein kinase
Methyl-CpG-binding domain protein 2
Monoclonal B lymphocytosis
Mega basepair
Induced myeloid leukaemia cell differentiation
protein
Mdm2 p53 binding protein homolog (mouse)
XI

MDR
Minimal deleted region
me/ me2/ me3 mono/di/tri methylation
MEACS
Non-muscle myosin heavy chain IIA exposed
apoptotic cells
MECP2
Methyl CpG binding protein 2
MeDIP
Methyl DNA immunoprecipitation
MI
Methylation index
miRNA
MicroRNA
MLL
Mixed-lineage leukaemia
MRE
methyl sensitive restriction enzyme
MSP
Methylation specific PCR
MYCN
V-myc myelocytomatosis viral related oncogene
MYD88
Myeoid differentiation primary response gene
MYF6
Myogenic factor 6
MZ
Marginal zone
n
Non-templated
NFkB
Nuclear factor kappa B
NGFR
Neural growth factor receptor
NHL
Non-Hodgkin lymphoma
NK
Natural killer
NLCs
Nurse like cells
NOTCH1
Notch homologue 1
OS
Overall survival
p
Palidromic
P2RY14
Purinergic receptor P2Y
PAK5
p21 protein (Cdc42/Rac)-activated kinase 7
PB
Peripheral blood
PBMC
Peripheral blood mononuclear cells
PC
Proliferation center
PCG7
Primordial germ cell 7
PDI
Protein disulfide isomerase
PI3K
Phosphoinositide-3-kinase
PLD1
Phospholipase D1
PPP1R3A
Protein phosphatase 1 regulatory (inhibitor) subunit
3A
PRAME
Preferentially expressed antigen in melanoma
PREs
Polycomb response elements
PRF1
Perforin 1
RAG
Recombination activating gene
RASGRP3
RAS guanyl releasing protein 3
RE
Restriction enzyme
RLGS
Restriction landmark genome scanning
RQ-PCR
Real time quantitative PCR
RSS
Recombination signal sequences
SAHA
Suberoylanilide hydroxamic acid
SAP
Shrimp alkaline phosphatse
SDF1
Stromal cell derived factor 1
SF3B1
Splicing factor 3b, subunit 1
SHM
Somatic hypermutation
SLC22A18 Solute carrier family 22, member 18
SLL
Small lymphocytic lymphoma
XII

SNP
Sp1
T
TBR
TBX3
TdT
TNF
TP53
Trx
TSA
TSG
TSS
TTT
TWIST-2
USP
UTR
V
VCAM1
VHL
VLA4
WHO
WISP3
XPO1
ZAP-70
ZNF 540

Single nucleotide polymorphism
Specificity factor 1
Thymine
Eomesodermin
T-box 3
Terminal deoxynucleotidyl transferase
tumour necrosis factor
Tumour protein p53 gene
Thioredoxin
Tricostatin A
Tumour suppressor gene
Transcription start site
Time to treatment
Twist homolog 2
Unmethylation specific PCR
Untranslated region
Variable
Vascular cell adhesion molecule 1
von Hippel-Lindau
Very late antigen 4
World health organisation
WNT1 inducible signaling pathway protein 3
Exportin 1
Zeta-chain (TCR) associated protein kinase 70kDa
Zinc finger protein 540

XIII

CONTENTS

Title ..............................................................................................................................(i)
Dedication .................................................................................................................. (ii)
List of papers............................................................................................................ (iii)
Abstract .....................................................................................................................(iv)
Declaration .................................................................................................................(vi)
Acknowledgements .................................................................................................. (vii)
Abbreviations ..............................................................................................................(x)
Contents ...................................................................................................................(xiv)

1) Introduction............................................................................................................... 1
1.1 Chronic lymphocytic leukaemia ....................................................................... 2
1.1 i Epidemiology and aetiology......................................................................... 2
1.1 ii Diagnosis ..................................................................................................... 3
1.1 iii Staging ....................................................................................................... 4
1.1 iv Infectious complications in CLL................................................................ 5
1.1 v Treatment..................................................................................................... 5
1.2 Normal B cells and B cell development ............................................................. 7
1.2 i Structure of the immunoglobulin molecule.................................................. 8
1.2 ii VDJ recombination.................................................................................... 10
1.2 iii The germinal center reaction and somatic hypermutation ....................... 12
1.2 iv Immunoglobulin diversity ........................................................................ 14
1.3 The CLL cell and CLL pathogenesis ................................................................ 14
1.3 i CLL cell of origin ....................................................................................... 15
1.3 ii The microenvironment in CLL.................................................................. 17
1.3 iii Evidence of antigen(s) involvement in CLL pathogenesis ...................... 21
1.3 iv The molecular nature of antigen(s) in CLL .............................................. 22
1.4 IGHV3-21 and IGHV4-34 CLL subgroups: IG sequences,
antigens and clinical implications ...................................................................... 23
1.4 i IGHV3-21 utilising patients ....................................................................... 23
1.4 ii IGHV4-34 utilising patients ...................................................................... 26
1.5 Prognostic markers in CLL............................................................................... 29
1.5 i IGHV gene mutational status ..................................................................... 29
1.5 ii Protein based markers: CD38 and ZAP70 expression .............................. 30
1.5 iii RNA based markers: LPL and CLLU1 expression................................... 31
1.5 iv Genomic alterations .................................................................................. 32
1.6 Genomic profiling technologies........................................................................ 42
1.7 DNA methylation.............................................................................................. 45
XIV

1.7 i Establishment and maintenance of DNA methylation ............................... 46
1.7 ii DNA methylation regulation ..................................................................... 48
1.7 iii DNA methylation in tumorigenesis.......................................................... 51
1.7 iv Hypermethylation ..................................................................................... 52
1.7 v Hypomethylation ....................................................................................... 53
1.7 vi DNA methylation and mutagenesis.......................................................... 54
1.7 vii Role of DNA methylation in CLL........................................................... 54
1.7 viii Disruption of DNA methylation regulatory mechanisms in
tumourigenesis ....................................................................................... 56
1.7 ix Use of DNA methylation markers in clinical routine............................... 57
1.8 DNA methylation technologies.......................................................................... 59
1.9 Epigenetic based treatment ................................................................................ 64
2) Thesis Aims ............................................................................................................ 65
3) Materials & Methods .............................................................................................. 66
3.1 Patient samples and patient characteristics ....................................................... 66
3.2 Ethical Approval ............................................................................................... 66
3.3 IG gene sequencing........................................................................................... 68
3.4 250K Affymetrix SNP array ............................................................................. 69
3.5 Illumina Infinium HumanMethylation27 and
HumanMethylation450 BeadChip array ............................................................ 71
3.6 Bioinformatic analysis of the Illumina human27
and 450 DNA methylation array data ................................................................ 74
3.7 Methylation-specific PCR analysis................................................................... 75
3.8 Real-time quantitative PCR analysis ................................................................ 76
3.9 Bisulfite sequencing.......................................................................................... 76
3.10 5-aza-2’-deoxycytidine and Trichostatin A treatment .................................... 77
3.11 Pyrosequencing ............................................................................................... 77
3.12 Statistical analysis........................................................................................... 78
4) Results & Discussion .............................................................................................. 80
4.1 Paper I: IGHV3-21 gene frequency in a Swedish population-based cohort..... 80
4.2 Paper II: High density array screening for genomic events in stereotyped
subsets of CLL ................................................................................................... 85
4.3 Paper III: Array-based methylation profiling in prognostic subsets of CLL .... 90
4.4 Paper IV: DNA methylation screening of CLL samples over time and within
different CLL compartments.............................................................................. 95
5) Conclusions........................................................................................................... 103
5.1 Paper I ............................................................................................................. 103
5.2 Paper II............................................................................................................ 103
5.3 Paper III .......................................................................................................... 104
5.4 Paper IV .......................................................................................................... 105
6) References............................................................................................................. 106
7) Papers I-IV............................................................................................................ 106

XV

1: INTRODUCTION

Chronic lymphocytic leukaemia (CLL) is a malignant clonal disorder characterised
by the accumulation of mature, functionally impaired neoplastic CD5+ B cells.
Originating in the bone marrow these cells slowly progress to infiltrate the peripheral
blood, lymph nodes and spleen. At both the clinical and biological level, CLL is
highly heterogeneous in nature. This heterogeneity gives rise to highly divergent
disease courses, ranging from an asymptomatic disease in some patients to an
aggressive and rapidly fatal condition in others.1 Determination of the events
contributing to CLL heterogeneity are key to identifying new prognostic markers that
in turn will lead to better subdivision of CLL patients, allowing better implementation
of optimal treatment regimes.
Over the past twenty years, studies of the B cell receptor (BCR) molecule on CLL
cells have denoted this molecule as a key player in CLL leukemogenesis and
prognostication. For instance, the mutation status of the immuno-globulin heavy
chain variable region gene (IGHV) has been established as one of the most reliable
prognostic markers in CLL.2,3 Moreover, studies characterising the molecular
structure of immunoglobulin (IG) gene re-arrangements support the notion that
certain CLL subsets sharing a distinct clinical outcome present with highly similar IG
rearrangements that may recognise a common antigen and confer a growth advantage
to the CLL clone.4-6 In certain cases, other factors such as recurrent genomic
alterations are known to contribute to CLL pathogenesis,7 however knowledge of
1

aberrant DNA methylation events in this disease is limited. Hence, this thesis will
focus on the relationship between the BCR structure, global genomic and DNA
methylation events that may contribute to CLL leukemogenesis in different
prognostic subgroups of CLL patients.

1.1: Chronic lymphocytic leukaemia
1.1 i: Epidemiology and aetiology
Today, CLL represents ~30-40% of all leukaemias and is the most commonly
encountered adult leukaemia in the Western world.8 Demonstrating a gender bias, the
incidence of CLL is almost twice that in men as in women.9,10 In Sweden alone, ~500
cases are diagnosed annually.11 The median age of CLL diagnosis is ~70 years,
however a third of patients are younger than 60 years of age at diagnosis.10,11 Firstdegree relatives of patients with CLL can have a 7-8.5 fold increased risk of
developing CLL and a 2-fold increase for other lymphoproliferative diseases,
suggesting a shared genetic component in familial CLL cases.12-15
To date, the aetiology of CLL is still largely unknown, however a number of linkage
studies have implicated some susceptibility loci in CLL. For instance, recent
investigations have identified susceptibility loci at 2q13 2q37.1, 6p25.3, 11q24.1,
15q23 and 19q13.32 thus providing the first evidence for the existence of common,
low-penetrance susceptibility loci in sporadic CLL.16-18 Monoclonal B lymphocytosis
(MBL), a condition characterised by the presence of <5.0x x109 clonal B cells per
litre of peripheral blood (PB), is now suspected to represent the pre-clinical stage of
2

CLL. MBL is common among the general population, occuring in 3-5% of
individuals over the age of 50 years.19-22 MBL can be categorised in to three
immunophenotypes; i) CLL-like MBL, CD5 positive with low CD20 expression, ii)
double positive CD5/CD20 MBL, resembling atypical CLL and iii) CD5 negative
MBL.20,22 CLL-like MBL is the most frequent MBL immunophenotype encountered.
Nevertheless, it must be kept in mind, that in the vast majority of MBL cases CLL
will not ultimately emerge.21 Unlike other forms of leukaemia, only suggestive
relationships between exposure to pesticides and certain solvents such as benzene
have been indicated in CLL aetiology, thus the effect of hazardous environmental
substances warrants further investigation.23,24
CLL is thought to be driven by a multistep pathogenic process. This involves the
evolution of CLL cells over time, gaining genomic and epigenetic alterations along
their evolutionary path to become increasingly tumourigenic. At each step, CLL is
driven by the combined contribution of intrinsic CLL defects with tumour promoting
extrinsic microenvironmental factors to finally form fully fledged CLL. However, the
specific nature and exact timing of initiating/transforming events in CLL
pathogenesis remain elusive.25-27 Some of these elements contributing to CLL
pathogenesis will be discussed in detail within the following sections.

1.1 ii: Diagnosis
The most characteristic feature of CLL is a peripheral blood B lymphocytosis of >5.0
x109/L.28 Morphologically, CLL lymphocytes are smaller than normal B lymphocytes
(Figure 1A). Furthermore, CLL cells appear to be more fragile resulting in the
formation of characteristic "smudge" cells on a blood film preparation.29
3

Interestingly, some reports claim that the amount of smudge cells found in routine
analysis

may in

fact be an independent

prognostic factor for CLL.30

Immunophenotypically, CLL monoclonal B cells typically express CD5, CD19,
CD20, CD23 and faint levels of surface Ig (sIg).28,31 The clinical features of CLL
such as lymphadenopathy and splenomegaly are generally indicative of later disease
stages where these symptoms arise due to the accumulation of lymphocytes in the
bone

marrow

(BM),

spleen,

lymph

nodes

(LN)

and

liver.9,32,33

Hypogammaglobulinemia is also common in late CLL disease and is associated with
an increased susceptibility to infection.34

Figure 1A. May-Grünwald-Giemsa staining of CLL cells in the bone marrow.

1.1 iii: Staging
In clinical practice, two staging systems are used at present, Rai and Binet staging,
however both of these systems have a limited ability to predict the clinical course at
an early stage of the disease. This is due to the fact that these systems are dependent
on the appearance of clinical symptoms which often occur late in disease.35,36 At
4

diagnosis, the majority of CLL patients are asymptomatic and it is only through
routine testing that CLL is identified in these cases. Approximately 30-50% of these
patients with an indolent CLL at diagnosis will progress, however predicting which
patients will progress is uncertain when using such clinical staging systems.37
Therefore, the need for new highly sensitive, specific and easily attainable prognostic
markers is warranted.

1.1 iv: Infectious complications in CLL
Infectious complications play a major role in the mortality of CLL patients. These
complications come secondary to the immune defects associated with primary CLL
disease and secondary to immunosuppression caused by certain treatments. In fact,
about 80% of CLL patients will experience infectious complications at some point
during their disease that can severely reduce patient quality of life. Moreover, 5060% of patients will die due to infection. Some examples of commonly contracted
infections are bacteremias and pneumonia caused by Streptococcus pneumoniae,
Haemophilus

influenzae,

Legionella

pneumophila,

Staphylococcus

aureus,

Salmonella, and others. Herpes viruses are also commonly encountered in CLL
patients.34 For instance, Epstein-Barr virus (EBV) can be a severe complication in
some CLL cases, moreover it is thought to be involved in the transformation of CLL
to aggressive Richters syndrome.38-40

1.1 v: Treatment
Currently, no outright cure for CLL exists, however various treatment strategies are
employed. Asymptomatic CLL patients undergo a watch and wait approach, where
5

treatment is only administered upon evidence of progressive or symptomatic
disease.28,41 The co-morbidity and fitness status of patients is taken into consideration
prior to the selection of a particular treatment regime.41 Patients with active disease,
that is patients with B symptoms, cytopenias and or complications from
lymphadenopathy, hepatomegaly, splenomegaly and or a lymphocyte doubling time
of <6 months are considered for treatment. Treatment with chlorambucil, an
alkylating agent has been considered a front line therapy for CLL for many decades
and remains an appropriate treatment today particularly in frail CLL patients.41 In the
recent past, fludarabine, a purine analogue in combination with cyclophosphamide, an
alkylating agent was deemed the standard first line therapy for CLL patients.42,43
Together fludarabine, and cyclophosphamide, work jointly to inhibit DNA synthesis
and initiate cell death.44 In some instances CLL patients may become refractory to
such combination chemotherapy treatment.45 In these cases, the additional use of
rituximab a monoclonal anti-CD20 antibody can improve the survival for such
patients.41 Hence fludarabine in combination with cyclophosphamide and rituximab
(FCR) is now considered the first line treatment of choice for fit CLL patients with
active disease.41
Choice of therapy not only depends on disease stage and patient fitness and
performance, it depends on the patient’s cytogenetic profile. New evidence
demonstrates that patients with deletion 11q can overcome the poor prognosis
traditionally attributed to this genomic alteration when treated with FCR. More
specifically, del(11q) patients treated with FCR have shown high rates of response,
survival and relapse free survival.46 In contrast, patients carrying del(17p) or p53
mutation have comprimisied function of their DNA damage response pathway hence,
6

treatment of such patients with conventional chemotherapy agents such as fludarabine
and cyclophosphamide that work through this pathway will not respond.41 Even with
FCR therapy these patients are shown to have a short progression free survival. In
these cases, the use of anti-CD52 (Alemtuzumab) antibodies can be effective.47 High
dose methyl-prednisolone in combination with alemtuzumab has also shown to be
effective in aggressive CLL patients with p53 defects.48 Today, the only available
potentially curative treatment is the use of allogenic stem cell transplantation;
however this is solely considered for younger patients with unfavourable prognostic
markers.41,49

1.2: Normal B cells and B cell development
In order to comprehend CLL pathogenesis, it is fundamental to understand the
function of normal B cells and the processes of normal B cell development, IG gene
rearrangement and B cell communication with antigen. B cells are the main cellular
components of the adaptive immune response that augment humoral immunity
through the production of antibodies. These cells function as key immune surveyors
that recognize foreign antigens and generate specific antibody responses that are
adapted to aid the elimination of specific invading pathogens. In order to produce
antibodies that specifically bind antigens, the B cell must undergo a process of
differentiation, a hierarchical pathway of development where each step is
characterised by a specific pattern of cell surface markers.50 B cell maturation occurs
in the bone marrow where stimulation from stromal cells and cytokines51,52 induce the
differentiation of pro B cells expressing CD43, CD19 and CD10 from stem cells.
Further maturation to the pre B cell stage denotes the earliest cell type synthesising a
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detectable IG, the cytoplasmic µ heavy chain. This µ heavy chain associates with
surrogate light chains and Igα and Igβ signal transducer molecules to form the pre
BCR.50,53
The next stage involves the production of the kappa or lambda light chains. These
light chains complex with µ heavy chains to produce IgM on the surface of the B cell
at the immature B lymphocyte stage. At this stage, these cells do not respond to
antigen, in fact on encountering antigen these cells may enter apoptosis or an anergic
state. The transition from immature to mature cells is marked by the co-expression of
µ and δ heavy chains producing membrane bound IgM and IgD, and this is
accompanied by mature functional competence. Subsequently, fully mature B cells
enter the circulation and lymphoid organs where they await antigen activation. Upon
antigen encounter, the naïve B cell initiates cell signaling resulting in growth and
proliferation of the B cell. This creates an amplified clone of plasma cells that secrete
the antigen-specific Ig. Furthermore, following activation, B cells leave a lasting
impression in the form of memory cells. These cells persist in circulation to produce a
more rapid immune response should they encounter future challenges by the same
antigen.50,53

1.2 i: Structure of the immunoglobulin molecule
The IG molecule is a membrane protein complex that is composed of two IG heavy
chains and two IG light chains (Figure 1B).54 Fundamental to the generation of a
diverse IG repertoire is the variable (V) region of the IG molecule. This region is
generated through a distinct process of gene recombination events at both the IG
heavy chain (IGH) and light chain (LC) loci known as VDJ recombination (see
8

below). The V region is characterized by conserved framework regions (FWR)
integrated among highly variable complementarity determining regions (CDRs),
CDR1, CDR2 and CDR3. In particular, the CDR3 is the most hypervariable region of
the IG molecule that is formed through the joining of three IG gene segments, the V,
diversity (D) and joining (J) gene segments (Figure. 1B).54,55 Thus, the CDR3 serves
as the main player in determining IG specificity at the antigen binding groove.50 As
such, IG constant regions (C) do not partake in antigen specificity; instead they
constitute the isotype of the IG and determine the effector function of the IG. These
regions may bind complement and receptor proteins to augment processes such as
lysis, opsonisation and cell de-granulation.50
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Figure 1B. Immunoglobulin structure ,VDJ recombination of the IGH locus and a
representation of the heavy and light chain CDR3.
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1.2 ii: VDJ recombination
As mentioned, the intricate process of VDJ recombination is a complex mechanism
involving a series of sequential rearrangements that play key roles in IG diversity.50,56
In short, the V region of the heavy chain is created by assembling distinct variable
(IGHV), diversity (IGHD) and joining (IGHJ) gene segments. There are 123-129
IGHV gene segments available for recombination, however only 38-46 of these are
functional gene segments. Moreover, 23 IGHD and 6 IGHJ functional gene segments
as well as 9 constant (IGHC) gene segments are available for rearrangement (Figure
1B).54,57,58 Rearrangement of the IGH locus commences at the pro B cell stage. On
maturing to the pre B cell stage, the rearranged IGH complexes with a µ constant
region to form IgM on the B cell surface.50
In addition, rearrangement of the kappa (IGK) and lambda (IGL) light chain loci
initiates during the pre-B cell stage, however only one specificity will be presented
(kappa or lambda) on the cell surface of the mature B cell. Unlike rearrangement
events at the IGH locus, only the joining of distinct V and J gene segments occurs at
the IGK and IGL loci. In total, 36-40 functional IGKV, 5 IGKJ and one IGKC genes
are available for recombination. At the IGL locus, 29-33 functional IGLV genes, 4-5
IGLJ and 4-5 IGLC genes are available for rearrangement. Due to the lack of D genes
at the light chain loci, the level of diversity is less than that observed at the IGH
locus.50,54,58
In short, the VDJ recombination mechanism is initiated by double stranded DNA
breaks introduced by two lymphocyte specific recombination activating gene (RAG)
enzymes, RAG 1 and RAG2.59-61 These enzymes work by forming a complex that
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specifically recognises recombination signal sequences (RSS) that flank the coding
V, D and J segments. These RSSs are made up of 3 distinct elements; a conserved
heptamer and a nonamer separated by a spacer element of 12bp or 23bp.57,59,60 The
length of this spacer element plays a key role in driving recombination specificity.62
This is explained by the 12/23 spacer rule that states that only pairs of dissimilar
spacer RSSs are efficiently recombined, so that spacers of 12 nucleotides will only be
recombined with spacers containing 23 nucleotides.56,63 In accordance with the 12/23
spacer recombination rule, a D gene segment will first combine with a J gene segment
forming a DJ complex. Following DJ joining a V gene will join to the DJ segment
forming a VDJ complex.50
After the above recombination events have taken place, DNA repair mechanisms are
employed to mend DNA breaks. DNA-dependent protein kinase complexes (DNAPK) are recruited to the broken DNA ends.62 Here, the DNA-PK recruits several other
proteins and DNA polymerases to the free ends. On aligning of the two free DNA
ends, the DNA-PK complex recruits the enzyme terminal deoxynucleotidyl
transferase (TdT).64 TdT works to add random non-templated (n) nucleotides to the
free DNA ends thus generating further IG diversity. Alternatively, deletion of
nucleotides through exonuclease activity can provide a further layer of diversity at
these junctional regions. Finally, DNA polymerases may insert additional nucleotides
as needed to make the two ends compatible for joining. A ligase IV enzyme finally
links DNA strands on opposite ends of the break to each other, completing the joining
process.59,64
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1.2 iii : The germinal center reaction and somatic hypermutation
Secondary lymphoid organs such as the lymph node and spleen provide unique
micro-environmental niches to allow naïve B cells the chance to encounter antigen,
proliferate and produce specific antibodies in a process termed the germinal centre
(GC) reaction (Figure 1C). Within these lymphoid organs are highly specialized GC
follicles that provide niches encompassing a network of antigen presenting cells, costimulator cells and cytokines. The GC reaction is initiated when the naïve B cell
encounters antigen in the extra follicular spaces. Upon activation of the cell it moves
to T helper cell zones. On recognizing the antigen, T helper cells produce CD40L
which binds to the B cell CD40 receptor to promote B cell activation.65 This induces
the B cell to transform into a highly proliferative centroblast within the dark zone of
the GC follicle.65 In an effort to generate antibodies with a higher affinity to the
initiating antigen, the process of somatic hypermutation (SHM) refines the sequences
of the BCRs by introducing single nucleotide mutations randomly into the IG
genes.66-68 In fact, SHM is a highly specialized process that occurs at a rate 106 times
higher than spontaneous mutation.66,69 At this stage,

B cells acquiring

disadvantageous SHM patterns will die by apoptosis.70 However, those that acquire
favourable antibody mutations move to the light zone of the follicle and are termed
noncycling centrocytes.71 These centrocytes bind their cognate antigen with the help
of follicular dendritic cells and T cells to differentiate into plasma or memory B
cells.65,72 Although GCs are considered the principal sites capable of sustaining SHM,
they are not thought to be the sole sites of such activity. It is thought that SHM may
occur outside of the GC and independently of T cell help.73-76 For instance, it has

12

been suggested that B cells contained within the extra follicular marginal zone (MZ)
of the spleen can also undergo SHM.73-76
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Figure 1C. The germinal centre reaction

SHM represents a second mode of IG diversification after VDJ recombination. The
process of SHM allows a further increase in IG diversity and the production of IGs
with a higher specificity,77 however, knowledge of the exact mechanisms governing
SHM are incomplete. SHM is known to involve the activation of induced cytidine
deaminase (AID), an enzyme that works to deaminate cytosine bases to uracil in
single stranded DNA creating a U:G mismatch.77 The mismatch is recognised by the
cell’s DNA repair enzymes that excise the uracil base, however, error prone
polymerases that work to fill in this gap result in the formation of mutations at this
site.77 These mutations are mainly substitution mutations; however insertions and
deletions also occur. Mutations are more commonly encountered in the CDR
sequences where certain hotspots within these regions appear to be targeted more
often to other regions.78-82
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1.2 iv: Immunoglobulin diversity
As mentioned, the vast variety of unique IG molecules making up the human Ig
repertoire is partially given by the intricate processes of VDJ recombination, SHM
and non-templated (n) and palindromic (p) nucleotide addition/excision at junctional
borders. In fact, due to these processes, the likelihood of finding two identical BCRs
is negligible. More specifically, when considering all permutations of V, D and J
genes at the IGH locus, the likelihood of the same VDJ recombination event
presenting in normal healthy persons is 1 in 6348. Taking into account the chances
that individuals carrying the same heavy chain carry the same kappa or lambda
rearrangement the probability further diminishes to approximately 1 in 2.3 million.
Finally, SHM events and the enzymatic addition and or removal of n and p
nucleotides at junctional regions further reduces the probability of two healthy
persons expressing identical BCRs to 2.3x1012.58

1.3: The CLL cell and CLL pathogenesis
On a blood film, CLL cells appear as small mature B lymphocytes containing a dense
nuclear structure, partially aggregated chromatin and a narrow rim of cytoplasm.28
However, CLL cells have intrinsic BCR signalling defects that are suggested to be
characterized in some cases by truncated CD79b Ig domains,83 defective assembly,84
glycosylation and folding of µ and CD79a chains.85 In other cases, somatic mutations
in the cytoplasmic domain of CD79b have also beed described.85,86 These
impairments may result in a low surface Ig expression and an inability to engage in
effective signal transduction, jeopardising the ability of the CLL cell to undergo
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apoptosis. Moreover, the high expression of the anti-apoptotic BCL2 family
described in CLL87 and the up-regulation of the cell cycle arrest protein p27KIP may
aid the accumlation of the CLL clone.88 Further propogated by continuous CLL cell
proliferation in lymph nodes,89 CLL cells thrive and out-compete normal B cells.
Once released to the peripheral blood, it is thought that CLL cells continually recirculate to the secondary lymphoid tissues, to receive growth and survival
promotional signals from accessory cells, cytokines and antigens contained within the
microenvironment. One theory proposes genetic and epigenetic alterations to act as
early initiating/driving events in CLL transformation.26,90-93 In this model,
microenvironmental extrinsic signals merely provide a support mechanism to the
CLL cells, whereby antigen(s) is proposed to administer a chronic stimulation to
BCR receptive CLL cells, propelling the clone along its tumorigenic path. In an
opposing theory, antigen is suggested to act as the key culprit in CLL initiation,
whereby long lived CLL cells acquire pathogenic genomic and epigenetic alterations
as secondary hits over time. Despite the lack of knowledge about the order and
sequence of such tumorigenic events, the proposed interplay between genomics,
epigenomics and microenvironment suggests a complex multistep tumorigeneis
model in CLL. However, key to this model is assessing the CLL cell of origin which
to date remains elusive.25,27,94

1.3 i: CLL cell of origin
Over the past two decades the perception of the candidate cell(s) of origin for CLL
has changed. Initially it was believed that a naive CD5+ B cell was the originator of
CLL. However, the discovery of divergent CLL subgroups (see prognostic markers
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section), IGHV mutated CLL, characterised by SHM of their IGHV genes and IGHV
unmutated CLL, characterised by the lack of SHM at their IGHV genes altered this
opinion. This finding lead to the hypothesis that unmutated CLL cells were derived
from CD5+ naïve pre GC B cells, whereas mutated CLL derived from antigen
experienced post GC memory B cells.2,3 In the recent past, it has been suspected that
both mutated and unmutated CLL cases derive from antigen experienced B cells, as
CLL cells were shown to have a similar gene expression profile to that of antigen
experienced memory B cells.95 The candidate single cell origin of CLL is considered
to be the marginal zone (MZ) B cell. The MZ B cell shares many CLL cell features
such as, an active membrane phenotype, and BCRs encoded by either mutated or
unmutated genes. Moreover, MZ B cells are also shown to demonstrate both poly and
autoreactivity. Finally like CLL cells, these MZ B cells can respond to T cell
dependent and independent antigens.25,75,94
Nowadays however, the notion of a single cell of origin is being challenged.27 Given
the fact that IGHV mutated and unmutated CLL have previously been shown to have
rather similar gene expression profiles, it is now suspected that perhaps the activated
state of CLL cells may mask larger gene expression differences between these
subgroups.27 If this is the case, then conceivably it is more likely that mutated and
unmutated CLL derive from two independent cell origins. Since CLL leukemogenesis
is considered to follow a long stepwise process perhaps spanning several steps in B
cell development, the prospect arises that transformation can occur anytime during B
cell maturation once IG heavy chain is expressed.27 Theoretically, this opens up the
possibility that CLL could be derived from multiple cell precursors.27 Today, it has
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been suggested that the propensity to generate CLL clonal B cells is already decided
at the hematopoietic stem cell stage.96,97

1.3 ii: The microenvironment in CLL
In vitro CLL cell culturing studies have long implicated the microenvironment to play
a crucial role in CLL survival. CLL cells in culture rapidly undergo apoptosis in the
absence of vital survival factors which are now known to occupy niches within
complex in-vivo micro-environmental networks.98-102 These networks involve active
molecule cross-talk between CLL cells, accessory cells, activated T cells and a
medley of soluble pro-survival chemokines and cytokines (Figure 1D). These
molecules communicate through ligand-receptor and adhesion molecule interactions
to activate autocrine and exocrine signaling in CLL cells.103-106 Overall,
microenvironmental interactions of CLL cells seem to mainly mirror those of normal
lymphocytes.103,107 However, certain distinct microenvironmental interactions
controlling CLL migration do exist that are not seen in normal B cells.108 In addition
to providing support to the CLL cell, the microenvironment is said to provide
physical protection from cytotoxic drug damage, thus contributing to treatment
resistance.109 CLL cell interactions within the bone marrow, peripheral blood and
lymph node microenvironment are discussed below.
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Figure 1D. The CLL cell microenvironment (Adapted from Burger et al 2009)110

Bone marrow
In the bone marrow, CLL cells come into contact with bone marrow stromal cells
(BMSCs).100,101 In vitro, CLL cells co-cultured with BMSCs have been shown to live
longer.100,101 This longevity is partially attributed to the interactions of BMSC CD54
and CD106 integrins with CLL cell CD49d/CD11a or CD11b/CD18 integrins. This
interaction is suggested to bring about protection from spontaneous apoptosis by
increasing anti-apoptotic signals such as BCL2.100,111,112 Accompanying survival
promoting events include the release of stromal cell chemokines such as, stromal cell
derived factor 1 (SDF-1) otherwise known as CXCL12. SDF-1 production is
constitutively produced by BM stromal cells in CLL patients.113 In response to SDF-1
release, CLL cells migrate towards these growth supporting accessory cells via their
highly expressed CXCLR4 receptors (Figure 1D).113,114 Once recruited, the stromal
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cells adhere to CLL cells via VCAM-1 to VLA4 integrin interaction to subsequently
activate anti-apoptosis pathways.100
Peripheral Blood
Unlike mononuclear cells in the peripheral blood of normal individuals, some cells in
CLL patients regularly morph into large nurse like cells (NLCs) that adhere to
leukemic cells in vitro.99 Similar to BMSCs, in-vitro co-culturing experiments have
indicated the importance of NLC derived SDF-1 in the prevention of apoptosis
through its interaction with CXCLR4 on CLL cells (Figure 1D). It is thought that
perhaps NLCs help counteract apoptosis through the activation of MAP kinase
ERK1/2 pathways that increase the expression of anti-apoptotic proteins like MCL1.115-117
The lymph node
The lymph node represents a specialized micro-environmental niche for CLL cells
since it is the proposed main site of antigen encounter, BCR signaling and
proliferation.105,118,119 In the past, CLL was solely considered to be an accumulative
disease driven by defects in apoptosis. Nowadays it is seen as a disease afflicted by a
concomitant increase in proliferation of the leukemic clone. Up to 1% of the CLL
clone is now known to proliferate daily, within specialized pseudo-follicle structures
known as proliferation centers (PCs).89,119 Large para-immunoblasts and prolymphocytes within these structures highly express the proliferation marker Ki-67
compared to smaller lymphocytes in the vicinity of the follicle.119 These large cells
are also known to have constitutive activation of the NFĸB pathway, thus promoting
cell proliferation through tight regulation of NFĸB target genes such as BCL-2 and
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MCL-1.119-121 In support of these findings, CLL cells isolated from LNs have been
recently shown to have an increased expression of active BCR signaling and
proliferation genes relative to cells from the blood or bone marrow.118
In PCs, subpopulations of T cells, stromal cells, macrophages and endothelial cells
provide a cocktail of signaling mediators. Normally, the B cell receives survival
signals via T cell CD40-CD40L stimulation. In CLL, increased numbers of T cells
concentrate round PCs in response to B cell CCL22 release.119,122,123 Together,
secretion of T cell derived cytokines like IL-4 and accessory cell chemokines such as
SDF-1 support the expansion of CLL clones by up regulating anti-apoptotic
SURVIVIN and BCL2 regulators.99,123
LN derived CLL cells are known to harbor higher levels of CD38, compared to PB
derived CLL cells.124,125 Additionally, in-vitro studies show an increase in CD38
expression upon CLL activation126 thus proposing CD38 positivity as a characteristic
of the CLL cell-LN microenvironment interaction. CD38+ cells have been reported to
interact with CD31 on stromal cells to promote CLL proliferation.127,128 In fact,
CD38+ cells are said to proliferate ~2X as fast as CD38- cells in vivo.129 It is thought
that CD38+ cells gain an enhanced migratory ability to home to favourable
microenvironments due to an elevated responsiveness to the CD31 stromal ligand.
Alternatively, given the strong association between CD38 positivity and increased
CD31+ vascularisation in lymph nodes, it is further proposed that the
microenvironment itself may induce CD38 expression.130,131 Given its function as an
accessory BCR signaling molecule, it is suggested that CD38+ cells can strongly
transduce signals from their BCR, unlike their negative counterparts.132,133 Altogether
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these circumstances have culminated to suggest that CD38+ cells constitute the
fraction of cells primed to proliferate in CLL.

1.3 iii: Evidence of antigen(s) involvement in CLL pathogenesis
Currently, the exact role of antigen(s) in CLL leukemogenesis is unknown.
Deciphering whether antigen(s) play vital a part in CLL initiation by providing a
proliferative stress or whether they contribute to CLL progression through chronic
stimulation of the CLL clone is an active area of current research. Despite these
uncertainties pertaining to time of antigen engagement in CLL pathogenesis, a
plethora of circumstantial evidence supports the involvement antigen at some stage of
CLL development. This evidence stems from the finding that compared to the normal
repertoire; CLL shows a biased use of certain IGHV genes, namely IGHV1-69,
IGHV3-7, IGHV3-23, IGHV3-21 and IGHV4-34.3,134,135 Additionally, IG sequence
analysis has described the presence of multiple CLL subsets with closely homologous
or stereotyped BCRs.4-6,134,136-138 More specifically, these stereotyped subsets are
characterised by an amino acid identity of ≥60% in the heavy chain CDR3 and
restricted usage of similar IGHV-D-J genes and light-chain genes. In fact, later
reports have evidenced that ~30% of CLL patients belong to subsets (>100 defined
today) carrying ‘stereotyped’ CDR3 sequences on their heavy and light chains.5,6
Considering the likelihood of finding two B cell clones with identical BCRs is almost
negligible, these findings are highly suggestive of antigen(s) involvement in
leukemogenesis.4-6,136,137
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1.3 iv: The molecular nature of antigen(s) in CLL
The specific nature of the antigen(s) involved in CLL is largely unknown. It is
suspected

that

foreign

antigens,139

auto-antigens94

and

super-antigens6

or

combinations thereof play a role in CLL leukemogenesis. The reactivity of CLL cells
to antigen stimulation has been shown to differ depending on the mutational status of
the BCR. For instance, unmutated BCRs have been shown to be polyreactive against
such molecules as bacterial lipo-polysaccharides (LPS). Moreover, unmutated BCRs
have demonstrated autoreactivity against insulin and DNA molecules.139,140 In
contrast, mutated BCRs appear to loose their polyreactivity upon acquiring mutations
through SHM.139
CLL BCRs including several stereotyped cases, have demonstrated homology to antiDNA, anti-rheumatoid factor, and anti-cardiolipin auto-antibodies.5 Moreover, BCRstereotyped CLL cells have been shown to bind intracellular autoantigen such as
cytoskeletal proteins vimentin and oxidised low density lipoproteins.141,142 More
recently, auto-antigen in the form of antigenic motifs on apoptotic blebs from dead
cells have been implicated in CLL leukemogenesis. It is thought that the BCR can
recognise these motifs leading to self stimulation and expansion of the CLL
clone.141,142 For example, unmutated CLL monoclonal antibodies have been shown to
specifically bind non-muscle myosin heavy chain IIA (MYHIIA9) exposed apoptotic
cells (MEACS). This event has been particularly evident in ‘subset #6’ patients
expressing IGHV1-69/IGHD3-16/J3 genes.143 In light of the latter finding, it is has
been suggested that CLL clones may arise from dual functional B cells that maintain
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their ability as scavengers of apoptotic residues, whilst sustaining their ability to bind
conserved bacterial cell motifs.142,144
Interestingly, self antigens have been noted to bind certain IGHV3 and IGHV4 BCRs
outside of the CDR3 region, instead binding to IG FWRs. Similarly, bacterial superantigens have been shown to bind FWR1, FWR3 and CDR2 regions of some IGHV3
BCRs.139,145,146 Details of these proposed superantigens are discussed below in
relation to the IGHV gene family in which they are suspected to have a role.

1.4: IGHV3-21 and IGHV4-34 CLL subgroups: IG sequences,
antigens and clinical implications
1.4 i: IGHV3-21 utilising patients
IGHV3-21 patients have been shown to demonstrate a poor clinical outcome and
aggressive disease regardless of their IGHV mutation status.4,135,137,147 In recent years,
studies of IGHV3-21 CLL have reported an abundance of evidence linking antigen
involvement to IGHV3-21 pathogenesis.4,6,135,137,148 For instance, approximately 50%
of CLL patients using the IGHV3-21 gene demonstrate stereotyped BCRs and these
are denoted as subset #2 patients. More specifically, subset #2 IGHV3-21 patients
carry stereotyped BCRs consisting of a conserved 9 amino acid long HCDR3
sequence (Figure 1E).137,148-150 In a large proportion of cases, the amino acid sequence
of these stereotyped HCDR3 regions are identical (ARDANGMDV). However, in
some cases sequences may differ merely by 1-3 amino acids at different positions.
Furthermore, in the majority of subset #2 cases, it is not possible to assign any D gene
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usage.137,147,148,150 Interestingly, IGHV3-21 stereotyped patients show restricted
expression of the IGLV3-21 gene.137,147,148 Altogether, these findings indicate the
recognition of a common antigen in IGHV3-21 subset #2 cases.4-6,137,147,148

Subset #2

Non-subset #2
IGHV3IGHV3-21
Heterogenous LC

IGHV3IGHV3-21
IGLV3-21

Homogenous CDR3
DANGMDV

Heterogenous CDR3

Figure 1E. A representation characterising IGHV3-21 stereotyped and non-stereotyped
BCRs

Non-stereotyped IGHV3-21 (non-subset #2) patients have a heterogeneous CDR3
and light chain gene usage (Figure 1E). Both stereotyped and non-stereotyped BCRs
have been reported to share an equally poor overall survival similar to that displayed
by other IGHV unmutated cases (see prognostic markers section). Nevertheless,
IGHV3-21 stereotypy has also been suggested to influence clinical behaviour. For
instance, patients carrying stereotyped CDR3s are proposed to have a more
progressive disease compared to non-stereotyped patients.5,149 Supporting this
proposal is the finding that IGHV3-21 patients with homologous HCDR3s more
frequently express high levels of the poor prognostic markers CD38 and
ZAP70.5,147,150
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IGHV3-21 sequences are predominantly border-line mutated. This finding can be
partially explained by the under-targeting of SHM across all regions of IGHV3-21
sequences compared to other IGHV3 subgroup genes.6 Interestingly, IGHV3-21
subset #2 patients have been shown to have lower targeting of mutations across all IG
regions except the HCDR2 compared to non-subset 2 IGHV3-21 sequences. That
said, several recurrent amino acid changes have been observed among subset #2
cases. Remarkably, a serine deletion at HCDR2 codon 59 is commonly detected in
stereotyped IGHV3-21 CLL sequences.6 This deletion appears to be both a CLL and
subset biased mutation. The finding of specific recurrent mutations in IGHV3-21
CLL further strengthens the role of antigen selection in CLL.
Interestingly, IGHV3-21 patients and in particular stereotyped patients, showed a
strong tendency to the retain germline configuration in the binding motif for
Staphylococcal protein A, a suspected superantigen in CLL.6 However, the biologic
and clinical implications of this finding (if any) remain unknown. Additionally,
mutated IGHV3-21 subset #2 cases have been shown to bind the intracellular autoantigen cofilin-1, an actin binding protein found localise with molecular complexes
on the cell surface at apoptosis.142
Finally, a geographic bias has been attributed to this poor prognostic IGHV3-21 gene.
For instance, Scandinavia has demonstrated the highest IGHV3-21 gene frequency
(10-13%)4,135,137,150 compared to other Southern European countries and North
America (~3-4%).5,151,152 These findings suggest that aside from geographical bias,
differences in ethnicity and/or environment may account for the varying frequency of
the IGHV3-21 gene seen globally. Nevertheless, it is also possible that biases in
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sample selection can contribute to the varying IGHV3-21 gene frequencies detected
around the globe.4,5,135,137,147,149-155

1.4 ii: IGHV4-34 utilising patients
IGHV4-34 gene usage is seen in approximately 8-10% of CLL patients. Two CLL
subsets carrying stereotyped IGHV4-34 BCRs namely subset #4 and subset #16 have
been described in CLL. Subset #4 is the most common stereotyped subset occurring
at an overall frequency of ~1%. This subset is characterised by a 20 amino acid long
CDR3 sequence and restricted usage of the IGKV2-30 light chain (Figure 1F).
Furthermore, these patients almost exclusively carry IGHV mutated genes.
Remarkably, these restricted biological features are associated with an indolent
disease course compared to non-stereotyped IGHV4-34 CLL patients displaying nonrestricted IG features (Figure 1F).5,6 The indolent disease course noted for these
patients, may in part be explained by the fact that these cases are associated with low
expression of the poor prognostic CD38 marker. Interestingly, subset #4 patients have
a low median age at diagnosis.5 Moreover, these patients demonstrate a potential
association with persistent infection by common herpes viruses such as EBV and
CMV.156 Recently, subset #4 cases have been shown to display extensive intraclonal
diversification suggesting a role of ongoing active antigen stimulation in these
cases.157

The second IGHV4-34 stereotyped subset, subset #16 is present at an overall
frequency of 0.3%. This subset is characterised by mutated IGHV genes, a restricted
IGKV3-20 light chain usage and a 24 amino acid long homologous CDR3 sequence
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(Figure 1F). However, as this subset is not commonly encountered little is known
about the clinical outcome for these patients.5
Subset #4

Subset #16

IGHV4IGHV4-34
IGKV2-30

IGHV4IGHV4-34
IGKV3-20

Homogenous CDR3
~24 aa

Homogenous CDR3
~ 20 aa
Non-subset
#4/16

Heterogenous
CDR3
Figure 1F. A representation characterising IGHV4-34 stereotyped and non-stereotyped
BCRs

In the germline state IGHV4-34 BCRs appear to be inherently autoreactive and may
bind to auto-antigens. However, since IG sequencing studies have revealed IGHV434 BCRs to be mainly mutated,6 it has been suggested that through SHM, IGHV4-34
BCRs can alleviate their auto-reactivity.158 More specifically, stereotyped IGHV4-34
cases demonstrate stereotyped amino acid sequence changes at their IGHV genes and
these changes are largely subset biased. Stereotyped IGHV4-34 subsets #4 and #16
have distinctive SHM distribution patterns in their HCDRs and HFRs compared to
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their non-stereotyped counterparts. For instance, subsets #4 and #16 carrying basic
lysine residues within their HCDR3 regions also incur stereotyped mutations in the
HCDR1 region resulting in the introduction of negatively charged residues. The latter
mutations are said to eliminate the potential DNA binding properties given by the
positively charged HCDR3 region. Furthermore, it is noted that in stereotyped
IGHV4-34 subsets the HFR1 motif conferring anti I/i reactivity is rather conserved
compared to non-subset cases. Hence, these subsets hold the potential to bind the I/i
blood group antigen or the B cell isoform of CD45 containing the Nacetyllactosamine antigenic determinant. Hence, through SHM, IGHV4-34 utilising
B cells lose their auto-reactivity transitioning to a more safe state so that they can
persist within the functional IG repertoire.6,94
In summary, the proposed stepwise model of CLL leukemogenesis suggests that the
survival of the preleukemic clone depends on the interaction of CLL cells with the
pro-survival microenvironment. Antigen(s) residing in this microevironment are
thought to provide transient or chronic stimulation to the CLL clone. Under this
model, antigen stimulation, aberrant genetic alterations and epimutations work
together in a stepwise fashion to create a thriving CLL clone. Transforming and
progressive events may occur at currently unknown discrete B cell developmental
stages or randomly depending on the type, efficiency and potency of promotional
microenvironmental signals. A summary of the genetic and epigenetic alterations
seen in CLL will be described within the following sections.
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1.5: Prognostic markers in CLL
1.5 i: IGHV gene mutational status
In 1999, two independent studies demonstrated that the IGHV mutational status could
categorise CLL into divergent clinical subgroups. Remarkably, the IGHV mutation
status allowed the subdivision of CLL into two disease entities where patients with
unmutated IGHV genes were shown to experience an inferior prognosis while,
patients with mutated IGHV genes demonstrated a superior prognosis.2,3 More
specifically, patients with IGHV unmutated genes have a more aggressive condition,
including evidence of advanced progressive disease, atypical peripheral blood cell
morphology, adverse cytogenetic features, clonal evolution, and resistance to therapy,
than those with mutated IGHV genes.2,3 As mentioned, an exception to this rule is the
presence of the IGHV3-21 gene (see the IGHV3-21 utilising patients section).
Today it is widely accepted that a 98% identity cut-off is best at making the clinically
relevant distinction between mutated and unmutated CLL. CLL patients who carry
IGHV genes with ≥98% identity to germline are considered unmutated whereas
patients with <98% identity to germline are denoted as mutated.2,3,159,160 Nevertheless,
applying this arbitrary mathematical cut-off to a biological event must be interpreted
with caution, particularly when dealing with borderline cases. Despite the advantages
of this robust prognostic marker, the methods used to obtain IGHV gene sequences
can be laborious, thus the search for more accessible prognostic markers conducive to
routine procedures are well sought after.
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1.5 ii: Protein based markers: CD38 and ZAP70 expression
CD38 expression was the first prognostic factor found to correlate with IGHV
mutational status, where high expression was shown to be associated with unmutated
genes and a poor prognosis.2,124,159,161 However, it has been evidenced that this
relationship does not always hold true.159,162,163 Another issue preventing the use of
CD38 expression as a substitute marker for mutational status is the lack of a
definitive threshold delineating what percentage of the CLL clone should possess
elevated CD38 expression in order to assign CD38 positivity.161,164 Moreover, CD38
has been reported to vary over time.124,162 Nevertheless, CD38 expression is
considered an independent prognostic marker, albeit not the strongest.165
Similarly, ZAP70 expression shows a good correlation to IGHV mutational status. In
general, the majority of mutated cases are shown to be ZAP70 negative, whereas
unmutated cases are mainly shown to be positive.166 Nevertheless, Rassenti et al
demonstrate that approximately 23% of patients show discrepant results that do not
correlate with mutational status.167 Discordant cases may frequently present with
other poor prognostic features such as del(17p), del(11q) and/or IGHV3-21
expression. For instance, 17p and 11q deleted patients have been found to have a low
expression whereas IGHV3-21 patients have been shown to have a high
expression.168 Interestingly, Rassenti et al have further shown ZAP70 expression to
be a better predictor of time to progression compared to IGHV mutational status.
Another advantage of ZAP70 measurement is the fact that ZAP-70 levels also appear
to remain stable over time.167
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ZAP70 measurement holds many advantages in that it can be easily measured by
readily available methods such as flow cytometry at the protein level and RQ-PCR at
the gene level 166,169 ZAP70 is expressed by other immune cells such as natural killer
(NK) and T cells which may influence ZAP70 expression analysis. Therefore, it is
required that CLL tumour B cells be purified away from such cells prior to ZAP70
expression analysis. Hence, the inconvenience of having to perform cell purification
prior to analysis makes measurement of ZAP70 expression non conducive for use in
clinical routine.

1.5 iii: RNA based markers: LPL and CLLU1 expression
Today, Lipoprotein lipase (LPL) gene expression serves as an independent prognostic
marker in CLL.170 Over a decade ago, gene expression studies identified LPL to be
differentially expressed in IGHV mutated and unmutated CLL.95,171 Although not
highly expressed in CLL, LPL expression is higher in IGHV unmutated patients
relative to IGHV mutated CLL patients.170 Expression further correlates with other
negative prognosticators such as high CD38, ZAP-70 expression and poor genetic
alterations.172 Predictive of a shorter treatment free survival and in most cases a
shorter overall survival, LPL expression in some instances has been deemed as a
superior independent prognosticator compared to IGHV mutational status.170,173
Moreover, its prognostic value is maintained independently of clinical stage.172-175
Very low LPL expression in normal peripheral blood mononuclear cells
(PBMCs)174,176 permits the use of non-sorted PBMCs from CLL patients for analysis.
Altogether, quantification of LPL expression by RQ-PCR may offer a cheaper, less
labour intensive method to identify prognostic subgroups of CLL patients.
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Differential display screening first identified CLL upregulated gene 1 (CLLU1) to be
differentially expressed in CLL. CLLU1 is highly expressed in IGHV unmutated
patients relative to mutated patients177,178 and is associated with other poor risk
characteristics namely advanced clinical stage, poor cytogenetics and high CD38 and
ZAP70 expression.173,178,179 Like LPL, high CLLU1 expression correlates to a shorter
overall survival and treatment free survival.173,178,180 Recently, the value of CLLU1
expression in IGHV mutated patients has revealed important prognostic information,
indicating those IGHV mutated patients with high CLLU1 expression to have a worse
prognosis relative to mutated patients with low expression.179 Additionally, CLLU1
expression appears to be exclusive to CLL cells and is stable over time.180 Hence,
determination of CLLU1 expression levels can be used as a reliable indicator of
tumour burden and is suggested to complement currently used techniques for minimal
residual disease (MRD) monitoring in CLL patients post therapy.181

1.5 iv: Genomic alterations
CLL is not defined by a single recurrent genomic alteration but rather by genomic
instability that frequently culminates into chromosomal aberrations which are present
in up to 80% of patients. Today, fluorescent in-situ hybridization (FISH) techniques
are implemented to detect the most common chromosomal alterations namely
del(13q), del(11q), del(17p) and trisomy 12, which are of important prognostic
significance in CLL (Table 1A).7
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Deletion 13q
Deletion at chromosome 13q14 is the most frequently encountered alteration
affecting up to 55-60% of CLL patients (Table 1A).7 Deletion of 13q most often
occurs as the sole alteration and is associated with a favourable prognosis and
indolent disease course.7 However, the prognostic significance of mono-allelic versus
bi-allelic deletions of 13q still remains controversial. Recently, a study revealed that a
similar time to initial treatment and overall survival was attained in both mono- and
bi-allelic del(13q) CLL patient groups.182 However, conflicting reports have
suggested that bi-allelic disease is associated with a tendency for better overall
survival compared to mono-allelic disease.183 That said, a study by Chena et al184 has
shown bi-allelic del(13q) patients to have a shorter treatment free survival relative to
heterozygous patients. Moreover, copy number neutral loss of heterozygosity (CNNLOH) events involving the loss of one allele and the subsequent duplication of the
alternative allele have been reported in CLL.183 Interestingly, these events have been
reported on 13q, particularly in patients showing bi-allelic deletions of 13q.183 These
observations suggest that the recurrence of CNN-LOH at chromosome 13 is an
important mechanism in CLL biology.
It is further argued that detection of del(13q) is not fully sufficient to define a CLL
with a good prognosis. For instance, the size of the clone carrying this alteration may
influence the disease course. Recent reports reveal that patients harboring a higher
percentage of del(13q) cells among their CLL clone have a worse clinical outcome
compared to those with a lesser percentage of cells.182,185 Further, evidence is given
by recent SNP profiling studies demonstrating the heterogeneity of 13q deletions in
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terms of alteration size, the genes they cover and the location of their breakpoints. For
instance, in most 13q deletion cases a minimally deleted region (MDR) covering
DLEU1, DLEU2, miRNA-15a and miRNA-16-1 genes is noted.186-188 Interestingly, a
study by Ouillette et al found that patients with del(13q) covering the MDR and the
RB gene positioned beyond the MDR region were associated with a higher Rai stage
compared to del(13q) patients not including the RB gene. Moreover, patients with
deletions covering the MDR in addition to the RB gene were more likely to be
treated. Hence, it appears that genes outside of the MDR play key roles in hampering
patient outcome.189
In del(13q) CLL, it is suspected that deregulation of miRNA-15a/miRNA-16-1 and
hence, deregulation of its downstream target the anti-apoptotic BCL2 gene, may
confer a selective cumulative advantage.186 The roles of DLEU1 and 2 are less clear,
however it is known that DLEU2 expression provides the primary transcript for
production of miRNA-15a/miRNA-16-1.190 Like miRNA-15a/miRNA-16-1, the DLEU7
gene is also positioned within the MDR in 13q deleted patients. DLEU7 plays a key
function as a potent NFkB inhibitor by interacting with members of the tumour
necrosis factor (TNF) receptor family.191 Moreover, studies on lung cancer cell lines
have shown DLEU7 expression to result in an increase in apoptosis.191 These
observations suggest that loss of DLEU7 may work in an additive manner with the
loss of miRNA-15a/miRNA-16-1 to augment the pathogenesis of del(13q) CLL.191
A recent mouse study has provided in vivo evidence suggesting that the
DLEU2/miRNA-15a/miRNA-16-1 locus controls B cell expansion by modulating
proliferation rather than affecting survival via the anti-apoptotic BCL2 gene.190 This
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study suggests that the function of this locus may be to tightly regulate cell cycle
entry in response to antigen. This is supported by the observation that
DLEU2/miRNA-15a/miRNA-16-1 expression was down-regulated in proliferating B
cells within germinal centers, thus establishing a tumor suppressor role for this locus.
Moreover, deletion of the DLEU2/miR-15a/16-1 cluster in mice was shown to cause
the development of indolent B cell-autonomous, clonal lymphoproliferative disorders
akin to the spectrum of CLL-associated phenotypes observed in humans. In addition,
this study demonstrated that miRNA-15a/miRNA16-1-deletion in human and mouse
leads to an accelerated B cell lymphoproliferative state that arises through modulating
the expression of genes controlling cell-cycle progression.190
Deletion 11q
Deletion of 11q is the second most common alteration in CLL (12-18%) and is
associated with an aggressive disease course and a poor clinical outcome (Table 1A).7
These

patients

are

often

characterized

with

abdominal

or

mediastinal

lymphadenopathy.192 Molecular characterization of del(11q) has identified a
minimally deleted region of 2-3Mb that includes the ATM gene. In the majority of
cases, ATM a tumour suppressor gene is considered the most likely candidate gene in
del(11q) CLL, since it is known to play a vital role in activating p53 and augmenting
the DNA damage response. Due to the integral role of ATM in maintaining genome
stability, mutation of ATM is strongly suggested to be involved in CLL
pathogenesis.192-194 Furthermore, approximately one third of 11q deleted CLL
patients display a somatic or germline ATM gene mutation.195,196
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Similar to del(13q) alterations, a marked complexity in the size and structure of 11q
deletions has been shown. For instance, a deletion of 11q can be discontinuous which
is indicative of complex genomic events taking place.183,197 In some cases 11q
deletions do not cover the ATM gene thus indicating the importance of alternative
genes in the critical region such as RDX. In other instances, genes outside of this
region such as the MLL gene may play a role in certain 11q deleted CLL cases.192,194
Recently, SNP analysis has demonstrated a MDR of 0.68Mbp at 11q22.3
encompassing the following genes, CUL5, RAB39, ACAT1, NPAT and KDELC.198
However, a more recent study describes a new MDR for 11q22.3 excluding the
RAB39 gene. 199
Deletion of miR-34b/miR-34c is also thought to play a role in del(11q) CLL
pathogenesis. Given the important function of micro RNA in guiding cell
proliferation and survival it is interesting to speculate that loss of miR-34b/miR-34c
may contribute to the aggressive disease state seen in del(11q) patients. In fact one
study demonstrates miR-34b-5p to target the TCL1 oncogene which may contribute to
TCL1 overexpression seen in CLL.200 Surprisingly, a conserved gene in the critical
region of 11q22-23 called ARHGAP20 is shown to be substantially up regulated in
11q deleted cases relative to patients to with no genomic alterations and trisomy 12
patients. Interestingly, 13q deleted patients also have a higher expression of this
gene.201 This finding supports a functional link between 11q and 13q deletions in
CLL. This notion is further endorsed by the finding that both MDRs in 13q and 11q
are syntenic to a single region in the zebra fish on chromosome 9. 202
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Trisomy 12
Today trisomy 12 is considered the third most common genetic alteration in CLL
occurring in 11-16% of patients (Table 1A).7 Trisomy 12 is caused by the duplication
of one of its chromosome pairs and is associated with an intermediate survival and
shorter time to treatment.7,203 Little is known of the pathogenesis behind trisomy 12
CLL, however, chromosome banding studies have identified a partial trisomy 12q13q15 in a minority of patients covering the MDM2 gene, a known gene deregulated in
CLL and a negative regulator of p53.204-207 Another candidate gene known to be up
regulated in CLL is the disease specific CLLU1 gene located at 12q22, however
CLLU1 expression was not found to relate to trisomy 12.177 Nevertheless, new gene
expression studies have provided further insight into trisomy 12 CLL pathogenesis.
Recently, four genes have been shown to be significantly associated with trisomy 12
CLL, including overexpression of the HIP1R gene at 12q24 and the MYF6 gene at
12q21. In contrast, the P2RY14 gene at 3q21-q25 and CD200 at 3q12-q13 were
shown to be under-expressed in trisomy 12 patients.208
Deletion 17p
Deletion of 17p, covering the TP53 gene, occurs in up to 10% of CLL patients and is
associated with a particularly poor survival and short time to treatment (Table 1A).7
Moreover, deletion of 17p is commonly observed to co-exist with other unfavorable
prognostic markers such as unmutated IGHV genes, high ZAP70 and CD38
expression.159 Additionally, del(17p) patients experience chemo-refractoriness as
chemotherapeutic reagents often work by inducing apoptosis or impeding the cell
cycle via the p53 pathway.209 Nevertheless, reagents which utilize p53 independent
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mechanisms such as alemtuzumab, an anti-CD52 monoclonal antibody can be
implemented in these cases.28 Recent studies have shown that the majority of 17p
deleted patients present with TP53 mutations on their other allele, however it was
also shown that a subset of CLL patients carry TP53 mutation without a deletion of
17p (Table 1A).210-212 In fact, patients solely carrying a 17p deletion or TP53
mutation alone have an equally poor overall survival similar to those patients carrying
both del(17p) and TP53 mutation. Thus, TP53 mutational status is an independent
prognostic indicator that is important for steering treatment choices.210-213
Deletion 6q
Today, approximately 6-7% of patients acquire del(6q) (Table 1A).214,215 However, it
is considered a progression marker as it is mainly detected in CLL patients at follow
up.216 Deletions are most frequently encountered at 6q21, however deletions at 6q27
have also been detected.214-218 No definitive tumour suppressor genes have been
accounted for in del(6q) CLL pathogenesis. The presence of del(6q) has been
associated with an increased white blood cell count and in some cases a more
extensive lymphadenopathy. Despite these associations, it does not appear to be a
negative prognostic indicator in CLL. That said, some studies have associated 6q
deletions with a shorter treatment free survival.215,219,220
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Table 1A. Summary of Genomic alterations in CLL.
Alteration

Del(17p)

TP53
mutation

del(11q)

Trisomy 12

del(13q)

Deletion 6q

Frequency

5-10%

1-5%

12-18%

11-16%

55%

6-7%

Candidate gene(s)

TP53

TP53

ATM

unknown

miR-15/16

unknown

Clinical outcome

poor

poor

poor

intermediate

good

progression

Use in clinical
routine

yes

no

yes

yes

yes

no

Translocations in CLL
In the past, cumbersome classical cytogenetic methods used to detect translocations
in CLL were often unsuccessful (see the Genomic profiling technologies section).
Hence, the frequency of CLL translocations was grossly under estimatated at this
time. Today, new and improved cytogenetic analysis has allowed the detection of
translocations in up to 30% of CLL patients, however these are largely non-recurrent
events.203,221 The presence of balanced and unbalanced translocations are linked to an
unfavourable clinical outcome in CLL.221 Interestingly, recurring breakpoints in CLL
translocations are shown to cluster in regions affected in other lymphomas, such as
1(q21q25), 1(p32p36), 2(p11p13), 6(p11p12), 6(p21p25), 13q14, 14q32, and
18q21.222 These regions are suspected to contain genes involved in CLL
leukemogenesis. For instance the t(14;19)(q32;q13) translocation involves the
juxtaposition of the transcriptional co-activator BCL3 gene to the IGH locus causing
an increase in BCL3 expression.223,224
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Genomic complexity
Recently, a correlation between genetic complexity and clinical outcome has been
described in CLL.225 For instance, a recent SNP study showed CLL patients carrying
more than two alterations to have a poorer overall survival.225 Similarly, patients
carrying a higher number of larger sized alterations have been associated with a
worse clinical outcome compared to those with smaller alterations.183 Additionally,
the genomes of patients carrying deletions of 11q and 17p are shown to be more
complex. For instance, a recent study demonstrated that patients with four or more
alterations greater than 5Mbs carried del(17p) or del(11q). Hence, due to the loss of
vital genes integral to genome stability, the genomes of 11q and particularly 17p
deleted patients are more complex and thus more likely to acquire further alterations
compared to other CLL patients.183

Novel alterations
Reports have indicated del(14q) as a recurrent alteration in CLL occurring in ~1.5%
of patients.226 It is has been shown that this aberration most often occurs in IGHV
unmutated patients.226 Furthermore, del(14q) patients were shown to have a high
occurance of trisomy 12. Deletion of 14q was associated with an intermediate
survival and shorter time to treatment although low sample numbers were
investigated. Deletions of 14q are heterogeneous in size; however, recurrent
breakpoints have been documented.226 Due to the frequency of these alterations and
their association with disease outcome, it is widely debated whether or not to include
deletions of 14q to the established FISH panel for detection of known recurrent
alterations in CLL.
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Through the use of new microarray studies, some novel alterations such as gain of 2p,
gain of 8q and loss of 4p, 8p and 22q have been identified,183,227-229 however no
consensus exists regarding the frequency of these novel alterations. This is likely due
to discrepancies in the array platforms employed and the study populations
investigated. Interestingly, gain of 2p covering the MYCN oncogene was recently
found in up to 28% of untreated Binet stage B/C patients.230 These patients also
experienced an increased MYCN mRNA expression, suggesting MYCN to have a
pathogenic role in these CLL cases.230 Additionally, a recent SNP-array study showed
this alteration to occur frequently in del(11q) patients.183 In patients with a loss at
chromosome 22q, the PRAME gene has been implicated as the candidate gene of
interest.228 Finally, dic(17;18)(p11.2;p11.2) a dicentric chromosome alteration has
been described as a novel recurring abnormality in CLL. This aberration is associated
with a complex karyotype, progressive disease, unmutated IGHV genes and an early
age at diagnosis relative to other CLL patients.231
Today, a small percentage of trisomy 12 patients 1.6-5% are known to carry a
coexisting trisomy on chromosome 19.232-234 More recent studies have shown this
genetic profile to occur exclusively in isotype switched sIg positive CLL.
Interestingly, this profile has been associated with the use of IGHV mutated genes
and high CD38 expression. Furthermore, it has recently been discovered that these
cases are often found to carry trisomy 18.235 Notably, trisomy 12 has been reported to
be associated with CLL patients expressing IgG-positive stereotyped unmutated
IGHV4-39/IGKV1-39 (1D-39) BCRs.236 In some instances, these cases have been
shown to be associated with the t(14;19)(q32;q13) translocation. As mentioned above
(in the translocations in CLL section), t(14;19)(q32;q13) causes the BCL-3 proto41

oncogene to become juxtaposed next to the IGH locus resulting in overexpression of
the BCL-3 protein and deregulation of NF-κB.177,223,237
With the advent of whole genome sequencing technologies a number of novel
mutations have recently been discovered in CLL. Studies have identified repeated
mutations in XPO1, a nuclear transport factor gene in ~2.4% of patients238,239 and
NOTCH1, a ligand activated transcription factor gene in ~12.2% of CLL cases.
NOTCH1 mutations are more frequently found in IGHV-unmutated/ZAP70+ cases
compared to IGHV-mutated/ZAP70- patients. More specifically, NOTCH1 mutations
are reported to occur in 18-20% of IGHV-unmutated/ZAP70+ patients and 4-7% of
mutated/ZAP70

cases.239,240

In

contrast,

a

frequency of

4%

in

IGHV-

unmutated/ZAP70+ and 1.5% in mutated/ZAP70 cases has also been reported.
NOTCH1 mutations in CLL have been frequently found to occur in trisomy 12
patients. Altogether, these findings suggest NOTCH1 activation to play a role in
IGHV-unmutated/ZAP70+ trisomy 12 CLL.238 In addition to these genes, recurrent
mutations of MYD88 and SF3B1 have been identified in 10% and 15% of CLL cases
respectively. Interestingly, SF3B1 mutations are shown to occur in CLL patiens
carrying deletion 11q.241

1.6: Genomic profiling technologies
Karyotyping ascertains gross chromosomal features such as chromosome number,
size and structure. Conventional cytogenetic staining techniques such as G, Q and Rbanding pinpoint the chromosomal regions affected by genomic alterations, however,
only large alterations (approximately from 5-10 Mb) across chromosome metaphase
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spreads are analysed.242 This method requires cumbersome cell culturing which has
often lead to a low percentage of successful karyotypes for CLL cells, given their
inherent inability to survive and proliferate ex-vivo.243,244 However, today the use of
growth stimulants such as CpG oligonucleotides, IL-2 and CD40L, have allowed
better detection rates in CLL.243,244
Today, in clinical practice, interphase FISH is instead the gold standard method of
choice for CLL, since it has the ability to detect smaller DNA target sequences (probe
size starting at 100-1000bp) without cumbersome culturing methods.245-247 FISH
involves the hybridization of a panel of fluorescently labelled region specific probes
to complementary DNA sequences at specific chromosomal regions. In CLL,
interphase FISH can detect clinically relevant and recurrent lesions in up to 80% of
CLL patients.7 The advantage of FISH relies on its ability to detect alterations even in
samples with a low percentage of tumour cells. Other advantages include its capacity
to detect homo- and heterozygous deletions and gains, as well as complex
chromosomal translocations and rearrangements. That said, FISH is limited in its
ability to detect aberrations that lie outside of the probe specific regions, making
global screening difficult. Techniques such as spectral karyotyping and multiplex
FISH simultaneously employ multiple probes sets in order to asses all chromosomes.
However, these technologies are costly and labour intensive and in some instances
limited by difficulties in probe design to certain chromosomal regions.245,247,248
Unlike FISH, comparative genomic hybridisation (CGH) has the ability to readily
examine the entire genome for alterations (approximately 5-10 Mbp in size). CGH
involves the quantitative hybridization of differentially labeled normal and tumour
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DNA to normal metaphase chromosomes. On the other hand, CGH has a low
sensitivity, requiring a high percentage of cells to have a particular alteration in order
to be detectable. Furthermore, such alterations as inversions and translocations can
not be identified.249
Today, the need for genome wide, high resolution scanning has culminated in the
development of array technologies and sequencing platforms allowing broader
characterization of known alterations and novel smaller genetic lesions contributing
to complexity. Array-comparative genomic hybridization (aCGH) and single
nucleotide polymorphism (SNP) array technologies investigate global genomic events
with the exception of repetitive regions, without the requirement of cumbersome
metaphase chromosome preparations. Using aCGH, copy number alterations (CNAs)
at a level of <100 kb can be detected.
In general, aCGH utilises the same principals as those of conventional CGH except
that instead of employing metaphase chromosomes as targets, thousands of short
DNA probes representing the genome are arrayed onto a chip.250 aCGH designed
using bacterial artificial chromosomes (BAC) tend to hold a lower power of
resolution251 compared to aCGH oligo-nucleotide arrays.252 Oligo aCGH permit a
higher resolution to BAC arrays since a higher number of probes made up of 60-mer
oligonucleotides are hybridised to the chip. Although a reliable method, aCGH is
limited by its inability to detect CNN-LOH events. In contrast, SNP array platforms
allow for the simultaneous detection of CNN-LOH events and CNAs at high
resolution down to ~10-25kb in size depending on the array.253
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SNP arrays are constructed using 25-30-mer oligonucleotide probes containing
specific SNPs. Each SNP position across the genome possesses two allelic variants
on the array, SNP A and SNP B. Today up to 106 probes can be spotted on the array.
After hybridising the sample of interest to the array, SNP copy number is determined
from the fluorescent signals arising from SNP A and B alleles. Normalising the SNP
data to a previously analysed healthy individual reference set determines
sample/reference ratios indicating the presence of chromosome alterations. One crux
of such SNP and array-CGH technologies is that they do not detect alterations that
occur in a low percentage of tumour cells.254 Failure to detect alterations also depends
on the platform and the algorithm used. For instance, some algorithms do not tolerate
normal cell contamination >20%, whereas some algorithms are adjusted to account
for normal cell interference.254
In the case of CLL, alternative optimization measures such as B cell enrichment
techniques help resolve the issue of normal cell contamination and low tumour
percentage.254 Recently, the Affymetrix 250K SNP array technology used in this
thesis, have been correlated to FISH analysis in CLL patients. Remarkably, this array
showed a 98.5% correlation to gold standard FISH analysis. On this basis, this array
was suggested for use in clinical routine. Furthermore, this array enabled detection of
the same prognostically relevant lesions as higher resolution arrays such as the
Affymetrix 6.0 at lower cost.254
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1.7: DNA methylation
1.7 i: Establishment and maintenance of DNA methylation
DNA methylation is a heritable epigenetic mark that involves the non-random
addition of a methyl group to the fifth position of a cytosine ring within CpG
dinucleotides (Figure 1G).

Figure 1G. DNA Methylation. Represetation of the addition of a methyl group to the fifth
position of the cytosine pyrimidine ring.

DNA methylation is accompanied by concomitant histone modifications that play key
roles in the control of gene activity and nuclear structure.255 For instance, DNA
methylation and repressive histone marks create a condensed genomic structure that
impedes the access or inhibits the binding of the transcription machinery resulting in
gene inactivation. Conversely, the presence of activating histone marks and the lack
of DNA methylation promotes an open chromatin structure supporting transcrition
and gene activation (Figure 1H). Together, these actions function to regulate normal
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cell differentiation, germline/tissue specific gene expression, genomic imprinting,
embryogenesis and transposon gene silencing.256-260

Figure 1H. Diagram representing the interplay of histone modifications and DNA
methylation in the control of gene activity and nuclear structure. TFs: transcription factors.

During early mammalian development, a global de-methylation event occurs during
pre-implantation. Once implanted, the embryo undergoes a wave of de novo
methylation.261-263 De novo methylation patterns are established through the actions
of DNA methyl transferases DNMT3A and B.264 The above actions lead to wide
spread global DNA methylation with the exception of CpG islands. Once established,
this global bimodal methylation pattern is faithfully maintained through the actions of
the ‘maintenance’ DNA methyltransferase DNMT1 enzyme. This enzyme is recruited
by the replication machinery to hemi-methylated DNA where it catalyses the transfer
of methyl groups to newly synthesized DNA strands after DNA replication.256,265
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During mammalian development, the bimodal DNA methylation pattern encounters
further de novo DNA methylating and de-methylating events in order to bring about
cell differentiation patterns. Unlike DNA methylation, mechanisms of DNA demethylation in mammals remain largely unexplored. That said, observations of global
de-methylation during embryogenesis have pointed to both passive and active modes
of action. Passive demethylation is said to occur when DNA methylation pathways
are inactivated and DNA methylation is diluted after subsequent replication cycles.261
Active DNA demethylation in mammals is thought to involve AID induced
deamination of methyl cytosine to thymine.266 This is followed by a base excision
repair by DNA glycosylase enzymes of the T/G mismatch.267,268 Alternatively, in
vitro studies have shown that DNMTs 3a and 3B can also deaminate 5-methly
cytosine.269 Imprinted regions are sheltered from active global demethylation as DNA
methylation maintenance proteins such as PGC7 and DNMT1 protect them.258,270,271
Moreover, it is also hypothesized that de-methylation may occur in somatic cells at
sequence specific sites.261,269

1.7 ii: DNA methylation regulation
The success of epigenetic marks governing gene activity and nuclear structure
depends on the strict regulation of the epigenetic machinery. DNMT enzymes,
histone modification enzymes, DNA-methyl-binding proteins, non-coding RNAs,
polycomb complexes amongst others work together to target specific genes for
activation or repression. To date, the order and sequence in which these regulators
crosstalk to co-ordinate epigenetic marks at specific targets is not fully elucidated.
Nevertheless, clues from normal cell development and differentiation provide some
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indication as to how DNA methylation may be regulated. In development, histone
marks are thought to play a role in establishing DNA methylation. Here, they act as
platforms permitting the recruitment, or inhibition of, the DNA methylation
machinery.255,272 In contrast, DNA methylation is considered to play a role in
maintaining histone modifications. Methylated DNA bound by methyl binding
proteins (MECP2 and MBD2) is said to act as a platform guiding the reassembly of
disrupted histone modifications post cell replication.255,273

Protection of CpG islands during development
Bimodal DNA methylation patterns set up during development are thought to be
directed through specific histone modifications. For instance, unmethylated H3K4
histones are associated with DNA methylation in many cell types.274,275 At
unmethylated H3K4 histones, it is proposed that DNA methylation is permitted
through DNMT3L which acts as a bridge to summon active DNMT3A and 3B
enzymes to H3.272,276 H3K4 methylation is said to be regulated by components of the
transcription machinery such as RNA polymerase II. Localized mainly at CpG
islands, RNA polymerase II works to recruit histone methyltransferases to H3K4.276
It is thought that repressive methylation marks at H3K4 inhibit the recruitment of de
novo DNA methylating enzymes, keeping CpG islands free of DNA methylation
repression. Alternatively, mouse studies indicate that CpG islands may escape de
novo methylation through the action of cis acting sequences such as Sp1 sites that
bind the Sp1 transcription factors and through unknown mechanisms hinder DNA
methylation at these sites.277
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Epigenetic regulation of cell differentiation.
In embryonic stem cells, differentiation requires pluripotency genes to be silenced. In
their active pluripotent state, these genes are found within an open chromatin
structure bound by acetylated H3 and H4, methylated H3K4 and unmethylated DNA
marks. Upon cell differentiation, gene silencing is thought to involve prompt
repression by protein repressor molecules.255,278 This action is said to signal the
recruitment of a histone methyltransferase G9 protein and histone deacetylase
enzymes, promoting the formation of a more compact chromatin.279,280 The actions of
G9 results in the methylation of H3K9, however at the same time by unknown means,
H3K4 is demethylated. H3K9 methylation acts as a platform allowing the binding of
heterochromatin proteins such as HP1. Additionally, G9 summons de novo DNA
methyltransferases DNMT3A and 3B to promote DNA methylation resulting in the
subsequent formation of condensed chromatin at these pluripotency genes.272,279,280
Polycomb target genes in cell type specific DNA methylation
Polycomb-multi-protein repressive complexes silence polycomb target genes vital for
mammalian development.281 More specifically, polycomb target genes encode
transcription factors important for embryogenesis, cell lineage specification, growth
and proliferation.282 It is thought that polycomb silencing of these developmental
genes may be overcome during germline differentiation. In embryonic stem cells
(ESCs), it is proposed that histones carrying easily reversible, bivalent repressive
(H3K27me3) and activating (H3K4me3) marks sit at these polycomb target genes,
allowing them to actively switch between active and repressive states depending on
the demands of the differentiating cell.283
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Interestingly, at the DNA level, the majority of these target genes stay unmethylated
during development.275 This is thought to be partially attributed to the fact that these
genes are mainly affiliated to CpG island promoters that are largely safeguarded from
DNA methylation during development. In certain instances, such as the
differentiation of ESCs to neural precursors, DNA methylation of polycomb target
genes has been described.275 DNA methylation of these genes is thought to be
mediated by polycomb complexes. Polycomb response elements (PREs), regulatory
sequence specific elements, are proposed to enable the binding of polycomb (PRCs)
subunits, marking the gene for repression.284 Binding of EZH2, the histone
methyltransferase subunit of the PRC2 complex, is known to catalyse the methylation
of H3K27. In vitro studies indicate EZH2 to interact with the DNMTs to mediate
DNA methylation of polycomb target genes.285

1.7 iii: DNA methylation in tumorigenesis
Today, it is widely accepted that alterations to the DNA methylome and changes to
histone modification patterns contribute to cancer pathogenesis. In particular, DNA
methylation of vital genes involved in key cellular pathways is now recognized as one
of the hallmark mechanisms of aberrant gene silencing (Figure 1I).286 Moreover,
hypomethylation of instable repetitive genomic regions is further thought to
contribute to cancer (Figure 1I). Unlike genetic lesions, such as mutations and
deletions, DNA methylation provokes gene silencing without changes to the DNA
sequence.287 In some instances, aberrant DNA methylation is suggested as an early
event in cancer occurring at the stem cell stage. However, other arguments support
aberrant DNA methylation as a late event, in tumorigenesis. Many of the DNA
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methylation changes found in cancer are said to merely reflect the patho-biology of
long lived progressive tumour cells and that these changes are mostly indicative of
passenger rather than driver epigenetic events.288 Overall, altered DNA methylation is
one component in a very complex epigenetic network that co-operates with intrinsic
cellular defects and tumour promoting extrinsic factors to aid carcinogenesis.
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Figure 1I. Illustration of DNA methylation in normal and cancer cells. (Adapted from Baylin
2005)289

1.7 iv: Hypermethylation
As previously described, globally, DNA is largely methylated with targeted regional
hypomethylation of most CpG islands in normal cells (Figure 1I). Vast DNA
methylation covering repetitive genomic regions and transposable elements ensures
the maintenance of genomic stability.260 On the other hand, hypomethylation of CpG
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islands allows the transcription of vital genes governing normal cell growth,
proliferation, differentiation and tissue specific gene expression.257,290 In cancer, the
opposite DNA methylation pattern ensues where targeted promoter hypermethylation
and global hypomethylation work in synergy with anomalous histone modifications
and interaction proteins to disrupt gene regulation.256,287,291-293 Pivotal to
carcinogenesis is the role of promoter DNA methylation and transcriptional silencing
of vital tumour suppressor genes.92,287,292 This largely involves methylation of
cytosines within densely populated CpG regions known as CpG islands spanning the
5’ end of many genes within their promoters. Nevertheless, new evidence suggests
that methylation of CpG island shores and shelf regions of low CpG density located
outside the vicinity of traditional CpG islands are fundamental to gene silencing.294,295
For instance, Doi et al have demonstrated a number of overlapping differentially
methylated loci involved in normal tissue programming, epigenetic reprogramming to
pluripotency and aberrant programming of cancer cells.294 Interestingly, these loci
were shown to be predominantly contained within CpG island shores. These findings
suggest that epigenetic changes encountered in cancer are likely due to the
reprogramming of the normal pattern of tissue specific differentiation and highlight
the importance of CpG island shores in regulating transcription of specific loci.294,295

1.7 v: Hypomethylation
In cancer, aberrant global hypomethylation has been proposed to inappropriately
active possible oncogenic genes,260 little evidence of this has been documented. More
importantly, hypomethylation of gene poor repetitive DNA sequences that account
for up to 30% of the genome are suspected to contribute to genome instability.296-298
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Furthermore, it has recently been described in mature B cell lymphomas that unlike
global hypo-methylation previously implicated in cancer, gene specific hypomethylation can fraternize with local DNA hypermethylation during tumorigensis.299

1.7 vi: DNA methylation and mutagenesis
DNA methylation can further influence genome stability through the introduction of
mutations at CpG sites. Methylated cytosines are subjected to a higher rate of
mutagenesis relative to unmethylated cytosines.300 This is thought to occur due to an
increased propensity of spontaneous deamination at methylated cytosines. These
mutations account for a large number of known point mutations contributing to
genetic disease and are said to account for up to 30% of all germline point
mutations.301,302 Moreover CpG sites in the coding regions of TP53 are methylated in
all human tissues.303 Approximately 25% of all inactivating mutations in cancer in
general can be attributed to transitions at CpG dinucleotides.302

1.7 vii: Role of DNA methylation in CLL
Like other cancers, the genome of CLL patients is hypomethylated compared to PB
mononuclear cells from healthy normal controls.304-306 Until recent times, epigenetics
was explored solely on a gene to gene basis. Nevertheless, this candidate gene
approach identified a number of DNA methylated promoters contributing to CLL
pathogenesis. For instance, TWIST-2, a transcription factor and well known silencer
of p53 function in other malignancies, was shown to be methylated predominantly in
IGHV mutated patients.307 Similarly, silencing of ZAP70 through methylation has
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been strongly correlated to IGHV mutational status.308 Additionally, loss or reduced
expression of DAPK1 through promoter methylation has been shown in a large
proportion of CLL.309 In mutated CLL, DNA methylation of CD38 and BTG4 has
been correlated to a favourable outcome, whereas DNA methylation of HOXA4 has
been affiliated to poor outcome.310
More recently, a study by Rush et al has demonstrated the genome-wide methylation
profiles of ten CLL patients.311 Using restriction landmark genome scanning (RLGS),
a restriction enzyme, 2D gel electrophoresis method, only a limited number of CpG
sites (~3,000) were analysed across the whole genome. Interestingly, between 2.5–
8.1% of the CpG islands were shown to be aberrantly methylated in CLL samples
compared with normal controls. Moreover, 193 aberrantly methylated sequences were
identified, of which 93% had CpG island characteristics and 90% showed homology
to genes or expressed sequences. Many of the genes identified were transcription
factors such as DERMO1, FOXE1, TBX3, and IPF1. Other loci known to play roles in
the nervous system such as TBR1, GLRB, and PAK5 were also identified, however
their role in CLL if any is still unknown. Finally, the GRM7 gene, a gene functioning
in the possible inhibition of cyclic AMP signaling in the induction of apoptosis was
identified as methylated in CLL patients.311
With the advent of higher resolution microarray and sequencing technologies, overall
DNA methylation scores have been indicated as strong independent predictors in
CLL progression.312 Patients with a higher genome- wide DNA methylation index
relative to their age expected index have been associated with an earlier indication for
therapy and Rai stage IV disease.312 On the other hand, patients displaying a lower
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index with respect to age have clinically stable, Rai stage 0-1 disease.312 Additionally
these new technologies have allowed the interrogation of repetitive sequences in CLL
patients. Here, aberrant hypomethylation at repeat sequences including ALU, LINES
and SATα, is shown to be more marked in 17p deleted cases. In addition, a lower
SATα methylation level has been shown to act as an independent marker predicting a
shorter time to first treatment in CLL.313 Furthermore, the methylation profiles of
CLL patients are shown to segregate according to CD38 expression.310

1.7 viii: Disruption of DNA methylation regulatory mechanisms in
tumourigenesis
In cancer, the epigenetic machinery fall victim to destruction and disorganisation. The
exact mechanisms involved in epigenetic deregulation are largely unknown. Genomic
loss or mutation to the DNA methyltransferases and other regulatory molecules are
suspected to contribute to epigenomic disarray. For instance, somatic mutations
decreasing de novo DNMT3A activity has been found in up to 20% of acute myeloid
leukaemia (AML) patients.314,315 Moreover, mutations in polycomb repressive
complex components have also been described. For example, mutations at tyrosine
641 in the SET methyltransferase domain of EZH2, are shown to change the substrate
specificity of EZH2 for various methylation states at H3K27 in non-Hodgkin
lymphoma (NHL).316 For instance, the Y641C mutation abrogates the enzymatic
activity of EZH2 against unmethylated and mono methylated H3K27. Remarkably,
this mutation allows this enzyme to carry out better catalysation and formation of
trimethylated H3K27 compared to the wild type enzyme.316 Additionally, in myeloid
disorders, inactivating mutations of EZH2 have also been reported.317
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Altered expression levels and improper activation of the epigenetic machinery are
also considered to be attributed to epigenetic disorder. For instance high expression
of DNA methyltransferases are thought to be involved in the pathogenesis of some
cancer cell types. Other studies have noted the over-expression of EZH2 to be
associated with cancer progression. One study by Chen et al suggests the over
expression of cyclin dependent kinases (CDKs) in cancer to aberrantly phosphorylate
and activate EZH2.318 Other in vitro prostate cell line studies suggest that increases in
EZH2 expression are due to genomic loss of miRNA 101.319 Interestingly, in MYC
induced lymphoma, MYC has been implicated to stimulate EZH2 expression by
repression of its negative regulator miR-26a, thus contributing to lymphomagenesis,
therefore a regulatory role for miRNAs in the epigenetic control of gene regulation
has been proposed.320

1.7 ix: Use of DNA methylation markers in clinical routine
In recent years, the plethora of genome wide DNA methylation studies have noted
differentially methylated gene patterns in different cancers.299,321-323 In some
instances, these methylation changes constitute tumour and tissue-specific changes
that contribute to tumorigenesis,294,295 thus marking these genes as possible candidate
prognostic markers and therapeutic targets in cancer. Despite the volume of these
differentially methylated candidates, very few have graduated to be true bona fide
prognosticators or therapeutic targets. One reason for this is the inability to decipher
true tumour specific differentially methylated genes from normal tissue and patient
specific changes.324 For instance, changes attributed to such factors as age, sex,325
hormones (androgens)326 and diet complicate matters since increasing age and poor
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folate diets leading to insufficient in vivo methyl stores can aid hypomethylation
events.327 Furthermore, changes attributed to patient treatment regimes and disease
progression may mask true tumour specific changes.
Another barrier preventing the possible use of such candidate markers in clinical
routine is the question of methylation stability over time. To date, little evidence
exists on this issue, since many studies are based on snap shot analysis of different
individuals and diseases.328 One study investigating bladder cancer metachronous
tumours from two individuals, has shown DNA methylation to be relatively stable
over time both within the individual and between patients.329 In contrast, a study by
Bjornsson et al328 focusing on absolute inter- and intra-individual DNA methylation
changes have identified substantial inter-individual age variation and considerable
differences occurring over time within individuals that would otherwise be missed by
group averaging. Interestingly, these changes were shown to be clustered within
family members. Hence, these findings support the age related loss of normal
methylation patterns as a mechanism for the late onset of disease and further highlight
the possible influence of genetic background on DNA methylation changes.324,328
That said, a study of DNA methylation in 40 monozygotic twins found 14 to have a
disconcordant degree of total DNA methylation, particularly those over 28 years of
age.330 Thus, the latter finding is indicative of environmental factors that are already
known to alter DNA methylation. While issues of stability and specificity prevail and
since the clinically relevant level of DNA methylation conducive to target gene
inactivation is unknown, use of differential DNA methylation changes as candidate
prognostic markers or treatment targets remain to be seen.
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1.8. DNA methylation technologies
DNA methylation quantification methods have evolved rapidly over the past two
decades. Initially, global DNA methylation levels were estimated using high
performance liquid chromatography (HPLC).331,332 This method, although highly
quantitative, failed to give information on the exact sequences afflicted with aberrant
DNA methylation. The need for region specific analysis, provoked the development
of cytosine methylation enrichment techniques employing methylation sensitive
restriction enzyme (MRE) digestion,333 McrBC methylation dependent enzyme
fractionation,334 5’-methylcytosine antibody immuno-precipitation,298 methyl-binding
protein capture methods335 and chemical bisulfite treatment approaches.336 Applying
enriched methylated DNA to various microarray and sequencing technologies has
allowed the interrogation of DNA methylation at individual regions, particularly
within CpG islands and gene promoters. More recently, advancing technologies have
enabled a more global view, uncovering the DNA methylation status of non CpG
island sites and repetitive sequences throughout the genome.337
Early sequence specific genome wide DNA methylation investigations utilised the
(RLGS) platform, an MRE based 2D gel method.338,339 This technology explored the
whole genome on a limited scale, deciphering methylation events contained only
within MRE recognition sites within a limited number of genes as reviewed in Fouse
et al.337 Plagued by false positive and negative results originating from incomplete
digestion the true reflection of DNA methylation at these sites is often hampered, as
reviewed in Esteller et al.297 Considering the disadvantages of RLGS and the fact that
it only assess ~3,000 CpG sites,311,338 the need for more reliable, higher resolution
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analysis paved the way for the use of high fidelity bisulfite treatment in combination
with microarray technology.
The onset of bisulfite conversion revolutionised DNA methylation analysis. This
allowed the reproducible change of unmethylated cytosines to be deaminated to
uracil, leaving methylated cytosines unchanged as they are refractory to treatment.336
However, bisulfite treatment reduces the sequence complexity of the genome
complicating its application to oligonucleotide arrays. Nevertheless, today bisulfite
treatment is considered the gold standard method of cytosine DNA methylation
enrichment336 for many high throughput DNA methylation sequencing platforms such
as shotgun bisulfite sequencing340 and DNA methylation microarray Illumina
human27 and human450 technologies. The 27K array allows the investigation of
~28,000 CpG sites covering ~14,000 genes, whereas the 450K array covers ~ 485,000
sites across the whole genome. These arrays, particularly the latter permit, the
interrogation of CpG sites both within gene promoters and outside of their coding
regions.341
In brief, microarray platforms interrogating DNA methylation at pre-determined CpG
sites342-344 generally offer less coverage (103-106) of the DNA methylome relative to
DNA methylation sequencing methods and next generation technologies (106107).337,345,346 Nevertheless, the microarray comprehensive high throughput arrays for
relative methylation (CHARM) tiling array provides a high CpG coverage similar to
that of some sequencing technologies ~106.334 In general, microarray platforms based
on the hybridization of bisulfite treated and MRE prepared DNA can provide single
CpG site resolution. In contrast, microarray platforms utilising immunoprecipitated or
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methyl binding protein enrichment, quantify DNA methylation across a region of
~1000 base pairs. Hence, the latter provide higher coverage of the genome yet at a
poorer resolution (as reviewed in Fouse et al).337 Such techniques as MeDIP and
MIRA-Chip rely on the faithful precipitation of DNA methylated sites using specific
antibodies against 5’methylcytosine or methyl CpG binding proteins which bind
methylated

cytosines.

Enriched

DNA is then hybridized to

a genomic

microarray.298,335 A summary of the advantages, disadvantages and characteristics of
some of the available DNA methylation platforms is described below in Table 1B and
1C.
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Table 1B: Summary of DNA methylation microarray platforms.
Microarray
PreCpG site
Advantages
Technology
Processing Coverage/
Resolution
Illumina
Bisulfite
~27,000/
Cheap
Human27
conversion
~1 bp
Reliable
Single bp
resolution
Illumina
Bisulfite
~450,000/
Reliable
Human450
conversion
~1 bp
Single bp
resolution
5
HELP-Chip
MRE
10 /~1000 bp
High genome
Promoter array
digestion
coverage
MIRA-Chip
(CGI array)
(Global
tiling array)
MeDIP-Chip
Promoter array
Global tiling
array

Sonication
or
MRE/MB
column

105/~1000bp

Sonication/
IP

105/~1000 bp
106/~1000 bp

CHARM
tiling array

McrBC
digestion

106/~1000 bp

106/~1000 bp

High genome
coverage
No need for
ssDNA
High coverage
Not limited by
restriction sites

Disadvantages
Low coverage
Promoter biased
No assessment of
repeat regions
Low coverage
Inability to assess
repeat regions
Low resolution
Limited to MRE sites
Low resolution
Limited to MRE sites

Low resolution
Enrichment bias
towards high density
CpG sites
Needs ssDNA
High coverage
No single site
Less biased
resolution
towards high
Limited to McrBC
density CpG
sites
sites compared to Can not interrogate
MeDIP
low density CpG
sites

IP: immunoprecipitation, MRE: methylation sensitive restriction enzyme, CGI: CpG island, MB
column: methyl binding protein column, CHARM comprehensive high throughput arrays for relative
methylation. HELP- HpaII tiny fragment enrichment by ligation mediated PCR. MeDIP- methylated
DNA immunoprecipitation, MIRA: methylated CpG island recovery assay, ssDNA: single stranded
DNA. Adapted from Fouse et al 2010.337
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Table 1C: Summary of DNA methylation sequencing platforms
Sequencing
Platforms

Preprocessing

CpG site
Coverage /
Resolution
105-106/~1 bp

Methyl-seq
/Help-seq

MRE
digest

Shotgun
Bisulfite
sequencing

Bisulfite
/sonication

107/~1 bp

MeDIP-seq

Sonication/
IP

107/
200-300 bp

Advantages

Disadvantages

High coverage
Interrogates repeat
sequences
Single bp resolution
High coverage
Interrogates repeat
sequences
Single bp resolution
High coverage
Interrogates repeat
sequences

Limited to MRE
sites

Difficulties in
assembling
bisulfite converted
sequences
No single site
resolution
Complicated to
analyse

IP: immunoprecipitation, MRE: methylation sensitive restriction enzyme, HELP- HpaII tiny
fragment enrichment by ligation mediated PCR. 337MeDIP- methylated DNA
immunoprecipitation, MIRA Adapted from Fouse et al 2010.

Although all the aforementioned technologies offer useful information, interpretation
of observations from these methods often need to be independently reconfirmed with
alternative methods. Semi-quantitative methods such as methylation specific PCR
(MSP)347 and bisulfite sequencing are often employed.348 MSP, although easy to
implement, is restricted in that it solely interrogates the CpG sites covered by the
primer. Unlike MSP, bisulfite sequencing is a labour intensive technique. That said,
bisulfite sequencing is much more advantageous than MSP since it readily
interrogates CpG sites contained within the amplified region determined by the
primers. Fully quantitative techniques such as pyrosequencing, can overcome some of
the disadvantages of the former methods. Specifically, pyrosequencing easily allows
the quantification of DNA methylation across a chosen site, often containing a
number of CpG sites with minimal DNA input.349,350
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1.9: Epigenetic based treatment
Epigenetic defects are heritable changes that do not affect DNA sequences; hence
their effects are potentially reversible through the use of methyl inhibitors and histone
deacetylation drugs. Today, the use of hypo-methylating drugs 5-azacytidine (5’aza)
and its more potent counterpart 5-aza-2’-deoxycytidine (DAC) has been approved for
the treatment of myelodysplastic syndrome patients. The use of histone deacetylase
inhibitors also represents another group of potential drugs that can be used in
epigenetic cancer therapy. Recently the first one of its type, suberoylanilide
hydroxamic acid (SAHA), has been approved for the treatment of cutaneous T cell
lymphoma.351
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2) THESIS AIMS

The overall aim of this thesis was to screen for genetic and DNA-methylation events
in divergent CLL prognostic subgroups and investigate DNA methylation over time
and within different CLL compartments. The specific aims were as follows:

- To determine the frequency of IGHV3-21 gene usage among a Swedish populationbased cohort using Sanger sequencing and assess the impact of IGV3-21 stereotypy
status on clinical outcome. (Paper I)

- To investigate genomic alterations in CLL patients expressing stereotyped and nonstereotyped IGHV3-21 and IGHV4-34 BCRs using 250K SNP arrays. (Paper II)

- To study DNA methylation profiling in prognostically diverse CLL subsets using
27K DNA methylation arrays. (Paper III)

- To evaluate the contribution of time and microenvironment on the global DNA
methylation profiles of CLL patients, by assaying patient-matched diagnostic and
follow-up samples and patient-matched LN and PB samples on 450K DNA
methylation arrays. (Paper IV)
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3: MATERIALS & METHODS

3.1: Patient samples and patient characteristics
In Paper I, peripheral blood (PB) was obtained form 337 patients at diagnosis
including, 325 CLL and 12 CLL/small lymphocytic leukaemia (SLL) cases from the
Swedish cohort of a Scandinavian population-based case-control study called SCALE
(Scandinavian Lymphoma Etiology).352
In Paper II, tumour material from 101 CLL patients was obtained from four
cooperating institutes in France (n=15), Greece (n=25), Denmark (n=4) and Sweden
(n=57). Samples mainly originated from peripheral blood (n=88), although samples
from spleen (n=5) and bone marrow (n=8) were also included. In total, 42 IGHV3-21
samples, encompassing 29 subset #2 and 13 non-subset #2 cases, and 59 IGHV4-34
samples, comprising of 17 subset #4, 8 subset #16 and 34 non-subset #4/16 cases
were analysed. Subsets were defined according to Stamatopoulos et al and Murray et
al.5,6 A CLL sample set (n=203) from a recent array study was used for comparison
purposes.183
In Paper III, 23 CLL samples (6 IGHV mutated, 7 IGHV unmutated and 10 IGHV321) were obtained from the Biobank at the Department of Pathology, Uppsala
University Hospital, Sweden. All samples were derived from peripheral blood. For
validation experiments, an independent set of 10 and 50 CLL samples were analysed
by MSP-PCR and RQ-PCR respectively. For control purposes, one peripheral blood
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mononuclear cell (PBMC) sample, one CD19 sorted B-cell sample and one negative
whole-genome amplified DNA control were additionally analysed. For comparison
purposes, 2 CLL EBV transformed cell lines (I83 derived from a mutated CLL
patient and HG3 derived from an unmutated CLL patient) were included for analysis.
In Paper IV, a total of 36 PB CLL samples obtained from the Swedish cohort of the
SCALE study352 were chosen for analysis. To study the DNA methylation profiles of
IGHV mutated and unmutated subgroups, sorted PB samples derived form 9 IGHV
mutated and 9 unmutated patients at diagnosis were analysed. Sorted PB samples
derived from these same patients were taken at follow-up to investigate DNA
methylation over time. (Patient-paired samples: IGHV mutated cases n=9 cases at
diagnosis and n=9 cases at follow-up and IGHV unmutated cases n=9 cases at
diagnosis and n= 9 cases at follow-up) In addition, a separate set of 10 patientmatched PB and LN samples collected from biobanks at Uppsala University and
Linköping University hospitals were analysed. PB from three age-matched normal
individuals and one whole-genome amplified DNA derived from PB were included as
controls.
All samples were diagnosed according to the WHO classification and the
International Workshop on Chronic Lymphocytic Leukaemia criteria (IWCLL).28 In
Paper I, samples with highly variable tumour load were included for analysis. In
Papers II and III, only samples with ≥70% tumour cell content were included for
analyses. In Paper IV, all samples were CD5+/CD19+ sorted. Clinical and molecular
data characterising Binet stage, IGHV mutational status, treatment and survival
status, and chromosomal alterations are detailed in Papers I-IV.
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3.2: Ethical Approval
All samples and clinical data included in the research described herein were collected
following strict ethical guidelines. Written informed consent was obtained according
to the Declaration of Helsinki. All personal data was de-personalised prior to analysis
and publication to maintain the privacy of the participant. Traceability procedures
were put in place allowing full traceability of patient samples and clinical data should
the participant wish to withdraw from such studies at any point. Each study was
approved by the local Ethics Review Committee from all collaborating institutions
mentioned in the relevant studies. Registration numbers of the ethical review board
decision from Uppsala University and the Karolinska Institute Sweden are as follows
Ups:01-082 and 2006/964-31/2.

3.3: IG gene sequencing
In all Papers, CLL patients were characterized according to IG gene usage,
mutational status and the presence of stereotyped and non-stereotyped receptor
sequences.5,6 These characteristics were detected through PCR amplification of
gDNA or cDNA using IGHV gene family specific framework 1 or leader primers.353
Consensus primers for the kappa/lambda FR1 and IGKJ/IGLJ genes6,147,149 were used
to amplify light chain IG rearrangements. Following amplification, most clonal
products were sequenced using the Big Dye terminator cycle sequencing reaction kit
(Applied Biosystems, Foster City, CA). Where direct sequencing was unsuccessful,
gel purification (Qiagen, Venlo, Netherlands) and/or cloning prior to sequencing was
performed. Sequences were then aligned in the IMGT database using the IMGT/V68

QUEST online tool (http://www.imgt.org).354 IGHV genes were denoted unmutated
where a ≥98% identity to the corresponding germline gene was determined.
Sequences with <98% identity were considered mutated. In Paper I, IGHV unmutated
cases were further classified into truly unmutated (100% identity to germline),
minimally (99-99.9% identity) and borderline mutated (98-98.9% identity).
Stereotypy status was determined based on established molecular IG sequence
criteria.5,6

3.4: 250K Affymetrix SNP array
In Paper II, 250K NspI SNP-arrays were applied to study CNAs and CNN-LOH
events in IGHV3-21 and IGHV4-34 stereotyped and non-stereotyped samples. Array
experiments were performed according to the standard protocols for Affymetrix
GeneChip® Mapping NspI-250K arrays (Figure 3A) (Gene Chip Mapping 500K
Assay Manual (P/N 701930 Rev2), Affymetrix Inc, Santa Clara, CA, USA).
Subsequent to array scanning using the GeneChip® Scanner 3000 7G, probe level
normalisation and SNP calling were accomplished using Affymetrix GeneChip®
Genotyping Analysis Software (GTYPE) 4.1.
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Figure 3A The 250K Affymetrix SNP array contains 262,000 SNP probes covering the
whole genome. In short, the tumor DNA is enzymatically fragmented using the NspI
restriction enzyme and adapters are added allowing PCR amplification of the fragments.
After amplification the fragments are further fragmented and end labeled. Following
hybridization of these labeled fragments to the array, copy number is estimated based on the
ratio of fluorescence signals detecting gains and losses. (Adapted from affymetrix.com)355

Single sample QC was performed using the Dynamic model algorithm and genotype
calls were made using the BRLMM algorithm.356 Quality control measures were
given as a neighbor score. This score was calculated by averaging the euclidean
distances between the log2 ratios of 5 consecutive SNPs. A neighbor score of ≤0.4
was applied as cut-off for sample inclusion. Log transformation of the data producing
log2-ratios allowed for a more symmetrical data distribution. Subsequently, copynumber normalization was performed using the Copy Number Analysis Tool (CNAT)
4.0.1 and normal samples (n=82) previously run at the Uppsala Array Platform were
used as a reference set for comparison.
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Copy-number analysis using the BioDiscovery Nexus Copy Number 3.0 software
(BioDiscovery, El Segundo CA, USA) operating the Rank Segmentation algorithm
was employed. CNAs were defined on significance thresholds (p-value) of 1x10-6 and
a log2ratio cut-off at ±0.2 for regions sized 200-500 kbp and ±0.15 for regions >500
kbp, respectively. These settings were defined through previously described real-time
quantitative PCR (RQ-PCR) validation experiments.183 To exclude polymorphic
regions, CNAs that overlapped with >50% of a known CNV region were not
considered as true CNAs and excluded from analysis. CNN-LOH analysis was
performed using SNP array-data, taking into account the fraction of normal cells
indicated from the flow-cytometry data.357 CNN-LOH regions larger than 3 Mbp with
less than 50% overlap to CNVs were acknowledged as legitimate CNN-LOH events.

3.5: Illumina Infinium HumanMethylation27 and
HumanMethylation450 BeadChip array
In Paper III, the HumanMethylation27 array (Illumina, San Diego, USA) was applied
to study the differences in methylation profiles between mutated, unmutated and
IGHV3-21 CLL patients. In Paper IV, the HumanMethylation450 array was
employed to study genome wide methylation differences between 1) IGHV mutated
and unmutated subgroups, 2) paired diagnostic and follow-up CLL samples and 3)
paired matched PB and LN CLL samples. All samples underwent bi-sulfite
conversion of genomic DNA according to the standard EZ DNA Methylation Kit
protocol. (Zymo Research, Orange, CA, USA).
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Following conversion, the DNA was whole-genome amplified, enzymatically
fragmented, precipitated, resuspended and hybridized over night to locus specific
oligonucleotide primers. The 27K array based on the infinium I assay design employs
locus specific oligonucleotide primers that are linked to individual bead types (Figure
3B). Two bead types correspond to each CpG locus – one to the methylated cytosine
(C) and the other to the unmethylated thymine (T) state. Following hybridization,
single base primer extension allows the detection of C or T nucleotides through a
fluorescent signal that is measured using the Illumina BeadStation GX scanner. The
intensities of the unmethylated and methylated bead types are measured and a DNA
methylation value, described as the Beta values or methylation index (MI), is
recorded for each locus via BeadStudio software. Unlike the 27K array, the 450K
array employs both infinium I and infinium II technologies (Figure 3B). The infinium
II design utilizes a single bead type. In this case, the methylation status is calculated
after hybridisation at the single base extension phase. The intensity of the fluorescent
signal emitted from this extension is scanned and measured. Since the 450K array
elicits the use of both infinium I and II assay designs, the array can increase genome
wide coverage across CpG sites compared to the limited coverage of the 27K array.
In both array types, the methylation status for each detected CpG can range between 0
(completely unmethylated) to 1 (completely methylated). MI cut-offs of ≥0.7 and
≤0.4 (average of all MI values in each group) were considered methylated and
unmethylated, respectively.
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Figure 3B. Diagram representing the principals of the HumanMethylation 27 and 450
BeadChip arrays. The 27K array is based solely on the infinium I design employing two bead
types per locus, one for the methylated (M) and one for the unmethylated (UM) state. The
450K array is based on both Infinium I and II design. The Infinium II design uses only a
single bead type (S). The methylated state is determined at base pair extension. (Adapted
from Illumina.com)341
73

3.6: Bioinformatic analysis of the Illumina human27 and 450
DNA methylation array data
To systematically identify differentially DNA methylated genes in paper III,
bioinformatic analysis of the methylation data was carried out using the statistical
computing language R (http://www.r-project.org) software. Similarly for Paper IV,
bioinformatic analysis of the methylation data was conducted using the R based
illumina methylation analyzer (IMA) package. In both studies, raw data was quantile
normalized, arcsin transformed and an empirical Bayes moderated t-test was then
applied using the ‘limma’ package to identify differential methylation patterns
between the various sample comparisons. The p-values were adjusted using the
method of Benjamini and Hochberg, and a level of p<0.05 was used as a cutoff.358 In
Paper III, to ensure only CpG sites with a large methylation differences were
obtained, an average geometric difference in MI of 0.45 between the IGHV mutated
and IGHV unmutated subgroups, 0.35 between the IGHV3-21 and IGHV mutated
subgroups and 0.35 between IGHV3-21 and IGHV unmutated subgroups was
applied.
In Paper IV, an average difference in MI of ≥0.40 was applied to decipher recurrent
differentially methylated sites between the IGHV mutated and IGHV unmutated
patients at diagnosis. To identify recurrent methylation differences between paired
diagnostic and follow-up samples, and patient matched samples from different
anatomical compartments, a paired t-test was adopted. Again, P values were adjusted
according to the Benjamini and Hochberg method and a P value of <0.05 was applied
as a cut-off. To determine recurrent differentially methylated sites across the paired
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over time and compartment samples, an average difference in MI of >0.20 was first
applied. On recognising the low number of recurrent sites passing the >0.20 threshold
an average difference ≤0.20 was employed. In order to assess the likelihood of small
methylation differences representing technical variation, R2 values were calculated
for diagnostic/follow-up pairs and patient matched compartment pairs and compared
to the R2 value reported by Illumina for technical replicates assayed on the 450K array
(R2>98).
To assess non-recurrent intra-individual methylation differences between patientpaired samples and patient-matched compartment cases that would otherwise be
masked by averaging of the data, intra-individual analysis based on non transformed
data of the paired samples was conducted. Specifically, the number of sites differing
by ≥0.4 in beta value (MI) between the individual diagnostic and follow-up pairs was
employed. Sites differeing by ≥0.4 in MI between the LN and PB patient-matched
pairs was first applied to determine non recurrent differences across the
compartments. Subsequently a filter of ≥0.3 in beta value was assessed.

3.7: Methylation-specific PCR analysis
In Paper III, methylation array results were verified using methylation specific
(MSP)-PCR for 4 differentially methylated genes. Methylated specific primers were
designed according to Li and Dahiya selection criteria using the Methprimer design
software (Bisearch, San Francisco, USA).359 Standard PCR protocol was applied and
bands were visualised on a 2% agarose gel.
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3.8: Real-time quantitative PCR analysis
In Paper III, to investigate the influence of methylation status on gene expression of
specific genes, the expression of 4 differentially methylated genes were tested using
RQ-PCR on 60 independent samples. Total RNA was extracted using the RNA
extraction Kit (Qiagen, Venlo, Netherlands) and reverse transcription was performed
using the MMLV-RT kit (Invitrogen, Carlsbad, CA) and random hexamers
(Fermentas, Burlington, Canada) according to the manufacturer’s protocol. RQ-PCR
primers were designed using the Primer3 software (Broad institute, Boston, USA)
(www.wi.mit.edu/). RQ-PCR analysis was performed using 2X SYBR green master
mix (Fermentas, Burlington, Canada) and expression was analyzed using the
Stratagene Mx 3005p (Stratagene, La Jolla, CA, USA) detection system and Max Pro
QPCR software (Stratagene).

3.9: Bisulfite sequencing
To confirm the methylation status of individual genes in Paper III, two genes
underwent bi-sulfite sequencing. Bi-sulfite sequencing primers (BSP) were designed
according to primer selection criteria as outlined by Li and Dahiya. 359 A touch down
PCR was applied as described in Paper III. The PCR product was cloned using the
Invitrogen TOPO TA cloning kit-2.1 TOPO vector (Invitrogen, Carlsbad, CA, USA),
and 10-12 positive clones per sample were selected. The product was subsequently
exonuclease/shrimp alkaline phosphatase (ExoI/SAP) purified and sequenced using
the BigDye Terminator Cycle Sequencing Reaction Kit (Perkin-Elmer, Foster City,
CA). Sequences were aligned and analyzed using the bisulfite sequencing web-based
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tool BiQ Analyzer software (Max-Planck Institut für informatik, Saarbrucken,
Germany).

3.10: 5-aza-2’-deoxycytidine and Trichostatin A treatment
To test for the re-expression of methylated genes after methyl inhibitor and/or histone
deacetylase inhibitor treatment, primary CLL cell samples and CLL cell lines were
cultured in supplemented RPMI-1640 media as outlined in Paper III. Confluent cells
were subdivided and cultured over 3 days in supplemented RPMI media treated with
one of the following treatments: 1) medium containing 5-aza-2’-deoxycytidine
(DAC) (5µM/L, Sigma Aldrich, St. Louis, MO) for 72 hours (medium was changed
every 24 hours), 2) medium containing Trichostatin A (TSA) (500nM/lit, Sigma
Aldrich, St. Louis, MO) for the last 24 hours, and 3) medium containing DAC for 48
hrs followed by addition of TSA for 24 hrs. Control cells were cultured in similar
way with no drugs added.

3.11 Pyrosequencing
In Paper IV, pyrosequencing was chosen to validate the methylation status of selected
differentially methylated genes seen on the Illumina 450K methylation array.
Pyrosequencing, a sequencing by synthesis method, gauges the primer directed and
polymerase extended incorporation of specific nucleotides to a bisulfite converted
DNA template. Pyrosequencing quantitatively measures the incorporation of
nucleotides since the amount of pyrophosphate emitted is ultimately converted to a
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proportional light signal. The degree of methylation is determined at each CpG
position in the analysed sequence through the ratio of T and C.350
First, bisulfite converted DNA was PCR amplified using a forward and 5’ biotin
labeled reverse primer pair designed using the PyroMarkTM software (Qiagen, Venlo,
Netherlands). Primers were designed to cover the exact CpG sites identified on the
450k methylation array. Once amplified, PCR products were immobilized on
strepavidin sepharose beads, denatured to form single strands and annealed to the
sequencing primer (designed by PyroMark

TM

software). Separation and annealing

steps were enabled by the PyroMark Q24 prep vacuum workstation. Following
annealing, CpG site methylation analysis was performed on the PyroMark Q24
pyrosequencing instrument and interpreted on the PyroMark Q24 software (Qiagen,
Venlo, Netherlands).

3.12. Statistical analysis
In Paper I, the statistical significance of IGHV3-21 gene frequency differences
incurred across our study and others was determined by a chi-squared test. Overall
survival was measured from the diagnosis date until the date of death or last known
follow-up. Time to treatment was calculated from the diagnosis date to the date of
first known treatment. Kaplan-Meier analysis visualized OS and TTT within the
different groups studied in the form of survival curves. A log rank test was employed
to determine the statistical differences in OS and TTT between the studied groups.
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In Paper II, statistical differences in the frequency and size of the alterations between
the studied groups were calculated via the Chi-square test, one way ANOVA test and
t-test where appropriate. In Paper III, statistical differences in expression as
determined through RQ-PCR were calculated by a t-test and represented in box plot
graphs. In Paper IV, statistical differences in the level of methylation determined by
pyrosequencing were calculated using a t-test. All statistical analyses were performed
using the Statistica 8.0 and 10.0 software (StatSoft, Tulsa, OK).
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4: RESULTS & DISCUSSION

4.1: Paper I: IGHV3-21 gene frequency in a Swedish
population-based cohort
A decade ago, the importance of IGHV3-21 gene usage as an independent prognostic
marker was discovered.135 In light of IGHV3-21 as a poor prognosticator irrespective
of mutational status, a myriad of studies were then dedicated to investigate the
prevalence and clinical outcome of this gene. Across European and North American
CLL cohorts, CLL was established to display a biased IGHV gene repertoire with an
over-representation of IGHV1-69, IGHV4-34, IGHV3-7, IGHV3-23 and IGHV3-21
genes.3,134,135,149 Additionally, studies continually demonstrated both mutated and
unmutated IGHV3-21 patients to experience a poor survival, similar to that of other
unmutated CLL cases utilising alternative IGHV genes.137,150,152 However, on
comparing the predominance of this poor prognostic IGHV3-21 gene across different
geographical regions, large variances in IGHV3-21 gene frequency were continually
noted. Remarkably, Scandinavia has been shown to present with a high IGHV3-21
gene frequency (10-13%)4,135,137,150 compared to other regions namely the USA and
Southern Europe (3-4%) (Table 4.1 A).5,151,152
On recognising the geographical bias of IGHV3-21 and the particularly poor clinical
outcome of these patients, attentions turned to the biological reasons behind such
findings. Sequencing of IGHV3-21 gene rearrangements noted a large proportion of
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cases to carry stereotyped HCDR3 sequences.

5,135,137,147,149

Moreover these

stereotyped cases were shown to frequently present with restricted IGLV3-21 gene
usage.137,149,150 Stemming from the findings of IGHV3-21 over representation and
IGHV3-21 BCR sequence restriction, the prospect of a specific antigen contributing
to IGHV3-21 leukemogenesis was suggested.25,144,148,360 Interestingly, some studies
have reported stereotyped IGHV3-21 (subset #2) patients to have a shorter time to
progression relative to their non sterotyped IGHV3-21 counterparts.149 That said,
other studies have not found such a correlation, thus no consensus exists regarding
the clinical impact of IGHV3-21 stereotypy in CLL.
Since many of these above findings are based on hospital-based CLL cohorts and are
subjected to large cohort selection bias, it was consequently of interest to determine
the frequency of IGHV3-21 gene usage among a CLL Swedish population based
cohort (n=337). Subsequently, we attempted to address the clinical impact of IGHV321 stereotypy and mutational status on CLL patient survival and progression.
This population-based study reports the Swedish IGHV3-21 frequency to be 6.5%.
Although this frequency is lower compared to previous Scandinavian rates
constructed from university hospital data (10-13%),4,135,137,150 the frequency still
remains higher relative to other large studies form the USA152 and the Mediterranean
(3-4%) (Table 4.1 A).5,151,152 In light of this finding, the differences in frequency
encountered between small hospital-based cohorts demonstrating an overrepresentation of IGHV3-21, such as Ireland (7.9%),361 Britain (9.6%),154 and the
Ukraine (5.8%)153 must be interpreted with caution, since discrepancies can be
introduced by such factors as sample size and cohort selection bias. That said, despite
81

the increased tendency to select for more aggressive CLL cases in hospital-based
studies, such reports from the Mediterranean and USA still find IGHV3-21 frequency
to remain rather low (3-4%).5,151,152 Despite the different nature of the CLL cohorts
studied, in this population-based report versus our previous hospital–based study we
reconfirmed that a true IGHV3-21 geographical bias exists in Sweden.

Table 4.1 A Comparison of IGHV3-21 gene frequency in large CLL cohorts from
Scandinavia, Mediterranean and USA

IGHV3-21
cohort

Current
Swedish
populationbased study

Hospital-based
Scandinavian
study4

Multicentre
Italian
study151

Multicentre
Mediterranean
Study5

USA
Study

IGHV3-21

6.5 %

10.1 %

4.1 %

3.5 %

2.6%

152

Other explanations for disparity in global IGHV3-21 frequency may be explained by
differences in genetic background, influencing the expansion of the IGHV3-21
precursor CLL cells. Interestingly, Iranian CLL hospital based studies have shown no
IGHV3-21 usage.362 Alternatively, it is plausible that the IGHV3-21 geographic bias
may reflect differences in the patient environment and the type of antigen exposure
encountered. Given that we find a similar proportion of stereotyped cases in this
report (14/22, 63.6%) as in other western CLL cohorts from the Mediterranean area
(16/32, 50%),5 Italy (32/58, 55.2%)151 and the US (25/63, 39.9%),152 the notion of a
native antigen primarily encountered in Sweden impacting on IGHV3-21 gene
frequency and leukemogenesis is less reasonable. On the other hand, non-stereotyped
IGHV3-21 BCRs, given their heterogeneous molecular structure, may enable the
binding of diverse antigens during leukemogenesis.
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This study, like many previous, has established IGHV3-21 patients to experience a
very poor overall survival (Figure 4.1 A).137,147,149-151 However, the clinical impact of
IGHV3-21 stereotypy is less clear. Given the suggestion of specific antigen
involvement in stereotyped IGHV3-21 CLL and since IGHV3-21 stereotypy has been
affiliated to disease progression,5,149,151 it was of particular interest to determine its
clinical impact on the disease. In a large collaborative European study incorporating
90 IGHV3-21 cases collected mainly from Sweden and Germany, no differences in
survival were encountered between stereotyped IGHV3-21 patients and their nonstereotyped counterparts.150 In support of these findings, studies from the US and
Italy encompassing 63 and 37 IGHV3-21 cases respectively corroborated the
disassociation between survival and stereotypy. As mentioned, smaller studies from
the Mediterranean (n=16 and n=32) have shown IGHV3-21 cases with stereotyped
receptors to undergo a shorter time to progression relative to non-stereotyped
cases.5,149 Perhaps these findings imply that the nature of the antigen may influence
patient clinical behavior. That said, our study could not corroborate this finding, since
no difference in time to treatment was seen between stereotyped and non-stereotyped
IGHV3-21 patients (p=0.68) (Figure 4.1 A).
Again, the possible reason for this disparity between our study and others is perhaps
explained by differences in cohort type and size. Alternatively, biological reasons
such as a higher expression of the negative prognosticator CD38 and the higher
occurrence of del(11q) documented in stereotyped relative to non-stereotyped
IGHV3-21 cases may partially explain the poor disease course seen in these earlier
studies.147 Although this study showed a trend towards having a higher frequency of
del(11q) in stereotyped IGHV3-21 patients, a higher expression of CD38 was not
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observed in these cases. Nevertheless, other studies have implicated a high WNT-16
expression and expression of alternative negative indicators ZAP70, CD49d, and
CD49b to contribute to the poor prognosis indicated in stereotyped IGHV3-21
patients.147

Figure 4.1 A. Kaplan Meier curve showing overall survival and time to treatment in IGHV321 patients.
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In summary, using a population-based cohort we reconfirm the geographic bias in
IGHV3-21 gene frequency previously identified in Scandinavia. Moreover, we
determined that IGHV3-21 patients experience an inferior outcome independently of
stereotypy. Regarding the prognostic role of stereotypy in IGHV3-21 CLL, further
large collaborative studies are needed before a definite conclusion can be made since
a large heterogeneity among published studies exists.

4.2: Paper II: High density array screening for genomic events
in stereotyped subsets of CLL
Although the advancement of new prognostic markers has allowed improved
subdivision of CLL, the causes of CLL still remain unknown and there is yet no
single genetic event indicated in all cases. Since the existence of multiple subsets of
CLL expressing ‘stereotyped’ BCRs implies a role for antigen(s) in CLL,5,6 and
considering ‘stereotypy’ may influence CLL clinical course, it was of interest to
determine if biases existed in the genomic profiles of stereotyped patients. As
mentioned, both the stereotyped IGHV3-21 subset #2 and IGHV3-21 non-stereotyped
counterparts are associated with a poor overall survival.137,150,152 Moreover, some
studies report subset #2 to be associated with a more progressive disease5,6,149 relative
to non stereotyped IGHV3-21, a finding we did not find evidence of among our own
cohort of Swedish stereotyped IGHV3-21 patients in Paper I. On the other hand,
stereotyped IGHV4-34 subset #4 is associated with an indolent disease course
compared to its non-stereotyped counterparts.5,6 Regarding IGHV4-34 subset #16,
little is known about this less commonly encountered subset. Thus, the aim of Paper
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II was to perform a detailed genetic characterization of clinically divergent
stereotyped CLL subsets using high-resolution SNP arrays, to identify genetic events
that may give clues to their pathogenesis and diverse clinical outcomes. In particular
this study focused on the comparison of poor prognostic IGHV3-21 subset #2 and
favourable prognostic IGHV4-34 subset #4 patients. In an attempt to identify
stereotyped specific events, the genetic profiles of stereotyped subsets were compared
to their non-stereotyped counterparts and a general CLL cohort.
SNP analysis revealed a higher number of poor prognostic IGHV3-21 samples to
carry alterations, i.e. 97% of subset #2 and 92% of non-subset #2 samples. In
contrast, the proportion of subset #4 samples bearing alterations was considerably
less (76%). Similarly, 75% of subset #16 samples carried aberrations, whereas 88%
of the more clinically heterogeneous non-subset 4/16 cases displayed alterations.
Besides the marked differences in the overall frequencies of samples affected with
CNAs, differences in the genomic complexity regarding the number, type and size of
alterations encountered were noted between the study groups. Overall, subset #2 and
non-subset #2 displayed a higher average number of aberrations compared to subset
#4. More specifically, 48% of subset #2 and 39% of non-subset #2 samples carried ≥3
alterations compared to 18% of subset #4 and 13% of subset #16 (Figure 4.2 A). In
fact, the majority (53%) of subset #4 patients carried only one alteration. The
increased genome complexity observed for IGHV3-21 patients, particularly for subset
#2, can be partially accounted for by the high frequency of the known recurrent
alterations observed. Interestingly, known recurrent alterations were detected in 90%
of subset #2 cases compared to, 54% of non-subset #2 patients. More noticeably, a
low frequency of the known recurrent alterations was seen among the favourable
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prognostic subset #4 patients (35%). Similarly, a low frequency was detected in
subset #16 (25%). However, IGHV4-34 non-subset 4/16 patients displayed a similar
frequency of known recurrent alterations compared to IGHV3-21 patients (59%).

Figure 4.2 A. Level of genomic complexity (CNA number and size).

Notably, poor prognostic deletions of 11q were more frequent in subset #2 and nonsubset #2 (31% and 23%) relative to subset #4 and IGHV4-34 non-subset #4/16
patients (0% and 12%). Furthermore, deletions of 13q were particularly high in subset
#2 cases and concurrent alterations at 11q and 13q were also found to be common in
these patients. In contrast, deletion of the good prognostic marker del(13q) was the
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only known recurrent aberration detected in subset #4 (35%) (Table 4.2 A). On
considering the larger number of alterations and the high frequency of poor genomic
markers carried by subset #2 in comparison to subset #4 patients, these findings
suggest that subset #2 are more likely to acquire genomic events relative to subset #4.
These events may represent important genetic events during the pathogenesis of
IGHV3-21 CLL particularly when considering the frequent finding of concurrent 11q
and 13q deletions, especially in subset #2 cases (Table 4.2 A). Hypothetically, these
aberrations may be acquired during the phase of active stimulation by (unknown)
antigens, which trigger the IGHV3-21 precursor cell to undergo rapid cell division
and hence, under such proliferative pressure acquire such clonal alterations. In
addition, it is interesting to speculate that these observations may account for the
adverse clinical outcome reported for IGHV3-21 CLL, particularly for subset #2
patients.

Table 4.2 A. Known genomic alterations in IGHV3-21 and IGHV4-34 subsets compared to a
general CLL cohort.
Subset/
del(11q)
del(13q)
trisomy 12
del(17p)
(poor
(good
(intermediate
(poor
non-subset
prognosis)
prognosis)
prognosis)
prognosis)
Subset #2
79%
0
0
31%
Non-subset #2

23%

31%

23%

7.7%

Subset #4

0
13%

35%
0

0
13%

0
0

Non-subset
12%
#4/16
General CLL 13%
cohort

44%

6%

3%

54%

11%

4%

Subset #16
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Recent reports suggest that not only the type of alteration but the size of the alteration
and the nature of their breakpoints influence clinical outcome. In this study, alteration
size accounted for another layer of genomic complexity. Size distribution analysis
showed subset #2 and non-subset #2 patients to have a higher number of alterations
greater than 1Mb in size compared to the other subgroups, particularly subset #4.
This can be accounted for by the high frequency of large known recurrent alterations
seen in IGHV3-21 patients, particularly in subset #2. However, further investigations
revealed that both subset #2 and non-subset #2 have similar average number of
CNAs/sample comparable to the level observed in our recent array-based study on
Swedish CLL.183 Hence, subset #2 and non-subset #2 cases do not appear to be more
complex when accounting for all genomic alterations compared to other CLL patients
in general. Their crux appears to come from their susceptibility to acquire known
recurrent alterations and larger sized alterations, which might be reflective of their
more active proliferative status.
On the other hand, subset #4, #16 and non-subset #4/16 showed a higher prevalence
of smaller alterations <1Mbp, owing to the lack of large recurrent alterations such as
del(11q), trisomy 12 and del(17p) in these groups. Additionally, 13q deletions in
subset #4 were shown to be of a smaller average size compared to those encountered
in the IGHV3-21 groups. Overall, on considering the lower number and size of
alterations in subset #4 and the lack of poor prognostic alterations compared to subset
#2, these features suggest that subset #4 patients are less likely to accumulate
genomic alterations. This is suspected to be due to a low proliferative drive stemming
from the IGHV4-34 BCR. Altogether, the lack of such genomic aberrations may in
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part be responsible for the indolent disease course experienced by subset #4 CLL
patients.
Novel events were identified on chromosomes 2q, 7q and 14q in IGHV4-34 patients;
however these were not attributed to any particular subset. Recurrent gains at 2q and
losses at 3p were demonstrated in two subset #2 cases. Recurrent CNN-LOH events
were mainly detected on chromosome 13q, although independently of stereotypy
status.
This study concludes that genomic aberrations were more common in subset #2 and
non-subset #2 compared to subset #4. The particularly high frequency of del(11q) in
subset #2 may be linked to the adverse outcome reported for these patients. In
contrast, the lower prevalence and size of CNAs and the absence of poor-prognostic
aberrations in subset #4 may reflect the indolent disease course seen in these patients.

4.3: Paper III: Array-based methylation profiling in prognostic
subsets of CLL
Aberrant DNA methylation is a key component in augmenting tumorigenesis, where
genome-wide hypomethylation and regional hypermethylation of tumor suppressor
gene (TSG) promoters are signature characteristics of many cancers.286 As
mentioned, in CLL, the candidate gene approach has revealed a significant
association linking promoter methylation to transcriptional silencing for a small
number of individual gene promoters, namely DAPK1,309 ZAP70308 and TWIST-2.307
Since the global methylation profiles of CLL were yet to be discovered, Paper III
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sought to investigate genome wide DNA methylation patterns in three divergent CLL
prognostic subgroups; IGHV mutated, unmutated and IGHV3-21 patients.
Considering the clinical and biological diversity of these subgroups, Paper III set out
to perform a detailed genome wide, albeit somewhat promoter biased, epigenetic
characterization using the Illumina 27K high-resolution DNA methylation
microarray, as an important means to identify differentially and aberrantly methylated
genes that may play a role in their pathogenesis and diverse clinical outcome.
Moreover, as methylation changes are reversible with the use of de-methylating
agents, whole genome scanning may help identify new therapeutic targets in CLL.
Hence, Paper III investigated the significance of DNA methylation in regulating gene
promoters by re-inducing the expression of methylated TSGs using the methylinhibitor 5-aza-2’-deoxycytidine and the histone deacetylase inhibitor TSA.
Corroborating other studies, Paper III demonstrated that CLL is hypomethylated
compared to normal healthy individuals on the global level.304-306 Furthermore, by
applying stringent bioinformatic approaches we identified for the first time distinct
differential methylation profiles in divergent CLL prognostic subgroups. A number of
significantly differentially methylated genes occupying key cellular pathways and
functions were revealed between the studied subgroups. For instance, 7 TSGs were
preferentially methylated and potentially silenced in the poor prognostic IGHV
unmutated subgroup (e.g. VHL, ABI3) (Table 4.3 A).363,364 In contrast, these genes
remained unmethylated and hence potentially expressed in the favourable prognostic
IGHV mutated CLL. That said, the IGHV mutated subgroup did display methylation
of 2 TSGs, PPP1R3A365 and WISP3366 that were unmethylated in IGHV unmutated
patients (Table 4.3 A). Similarly, most methylated TSGs found in the IGHV
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unmutated subgroup were found to be unmethylated in IGHV3-21 patients, one
exception was the preferential methylation of the SLC22A18 gene.367 These
observations suggest that the specific methylation patterns of certain TSGs may play
a role in the pathogenic pathways that lead to these clinically divergent subgroups.
That notwithstanding, many of the TSGs identified in this study have been implicated
in several other cancers, however, their role in CLL has yet to be determined (Table
4.3 A).
Table 4.3 A. A brief summary of the differentially methylated genes identified between
IGHV mutated and IGHV unmutated CLL
Gene
IGHV
IGHV
Examples
function
MutatedUnmutated-CLL
CLL
Aiding
Methylated
Unmethylated
ADORA3368
tumourigenesis
ANGPT2369
Suppressing
tumourgenesis

Unmethylated

Methylated

VHL363, ABI3364
LCOD1370

Anti-apoptotic

Methylated

Unmethylated

BCL287

Pro-apoptotic
genes

Unmethylated

Methylated

BCL10371

Certain cellular pathways, such as NFκB, PI3K/Akt and MEK/ERK, are dysregulated
in CLL B cells leading to activation of anti-apoptotic pathways.116,117,120,372,373 Our
data strengthens this idea and further indicates that certain genes involved in such
‘proliferative’ pathways may be regulated by DNA methylation in CLL. For example,
genes activating the NFκB pathway, such as ADORA3368 and CARD15,374 were
specifically unmethylated in the unmutated CLL subgroup. Similarly, the
LOC340061375 and PRF1376 genes, which activate the NFκB and MAPKinase
pathways, respectively, were unmethylated and therefore potentially expressed in
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poor-prognostic IGHV3-21 CLL compared to IGHV mutated CLL. In line with these
findings, genes repressing the NFκB pathway (LCOD1 gene)370 and MAPKinase
(ZNF540 gene)377 pathways were generally methylated in both IGHV unmutated and
IGHV3-21 samples in contrast to IGHV mutated CLL. Again most genes have not
been associated with CLL, while many are known to be involved in the
tumourigenesis of several other cancers and leukaemias.
Genes known to facilitate tumourigenesis within other cancer types, such as IFNB1378
and IL17RC,379 were noted to be preferentially unmethylated in the IGHV unmutated
and IGHV3-21 CLL subgroups in comparison to IGHV mutated CLL. Similarly the
LMO2 oncogene380 and RASGRP3381 which regulate B cell proliferation by
facilitating B-cell receptor-Ras signaling, were unmethylated in IGHV3-21 samples.
Thus, the above data indicates that poor-prognostic CLL subsets favor expression of
genes aiding tumor proliferation.
Interestingly, array analysis provided insights into the deregulation of anti- and proapoptotic genes in IGHV mutated CLL. For instance, PLD1, a known anti-apoptotic
gene,382 remained unmethylated in IGHV mutated CLL samples. On the other hand,
pro-apoptotic genes such as BCL10371 and TP5313383, were methylated in IGHV
mutated samples unlike IGHV unmutated CLL.
In short, genes related to prognosis, for instance the ANGPT2369 gene, which has been
implicated in progressive CLL disease states were shown to be preferentially
methylated in the favourable prognostic mutated CLL cases while being
unmethylated in unmutated CLL (Table 4.3 A). In addition, the NGFR gene which
has been associated with a favorable prognosis in ALL,384 was shown to be
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unmethylated in IGHV mutated CLL and showed increased expression on the RNA
level within this subset.
Independent verification of array results was performed for a select number of genes
of different functionalities using an independent CLL sample set. MSP-PCR semiquantitatively verified the methylation status of four methylated genes (PRF1,
ADORA3, IGSF4 and BCL10), RQ-PCR demonstrated the correlation between gene
expression and methylation status for 4 genes (eg. VHL, ABI3 and NGFR) in an
independent CLL cohort and finally, bi-sulfite sequencing further quantified the
degree of methylation for two genes (ABI3 and VHL).
Finally, through the inhibition of DNA methylation using methyl- and HDAC
inhibitors, this study evidenced the induced expression of methylated TSGs (e.g.
IGSF4, ABI3 and VHL) in unmutated CLL primary samples. In general, although a
low induction of gene expression was observed with methyl inhibitor treatment only,
a more pronounced effect was seen when the methyl inhibitor and histone acetyl
inhibitor drugs were applied in combination. That said, the low induction can be
partially explained by the fact that CLL primary cells do not proliferate at a high rate
under in vitro conditions. These data indeed strengthen the role of DNA methylation
in regulating promoter expression and open up the possibility of targeted therapy in
CLL (Figure 4.3 A).
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Figure 4.3 A. Re-expression of DNA methylated tumour suppressor gene ABI3 using methyl
inhibitor DAC (5-aza-2’ deoxycytidine) and histone acetyl inhibitor Tricostatin (TSA).

In conclusion, Paper III shows distinct methylation profiles encompassing a number
of candidate genes involved in cellular pathways regulating proliferation and
apoptosis in IGHV unmutated/mutated and IGHV3-21 CLL and thus underlines the
critical role of epigenetic changes during leukemogenesis.

4.4: Paper IV: DNA methylation screening of CLL samples over
time and within different CLL compartments
On identifying differential methylation profiles in IGHV mutated and unmutated CLL
in Paper III, we set out to further investigate their methylation profiles using a higher
resolution 450K global DNA methylation microarrays. More specifically, we aimed
to determine whether the DNA methylation profiles of these subgroups changed over
time during the course of disease and whether DNA methylation of CLL cells
differed according to the anatomical site from which the cells resided. The first part
of this study, in accordance with Paper III, again identified IGHV mutated and
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unmutated CLL to have differential DNA methylation profiles, albeit on a larger scale
than previously reported. Specifically we found 2239 differentially methylated sites
between these subgroups compared to a mere 99 sites identified previously. We found
a relatively even distribution of differentially methylated sites across the whole
genome. However, we noted that the largest proportion of differentially methylated
sites was located outside of the CpG islands and within gene bodies. Only recently
with the advent of whole genome analysis has the relevance of this latter finding
come to light. Traditionally DNA methylation analysis has solely focused on CpG
islands, particularly within gene promoters, since it is here that gene regulation is
primarily regulated. In Paper III, we identified DNA methylation of ADORA3,
positioned approximately 1kb away from the promoter, to have a regulatory function
on gene expression. On a much larger scale Irizarry et al295 further corroborates this
finding, showing the majority of altered DNA methylation sites in colon cancer to
reside outside of CpG islands in regions up to 2kb distant from the CpG island in
regions called CpG island shores. Moreover, these sites were shown to correlate to
gene expression.
Gene ontology analysis identified a number of enriched physiological and molecular
functionalities, most of which have not been implicated in CLL before. Many genes
were known as members of established signaling pathways, whereas others were
shown to be involved in other cancers. For instance, CpG sites within DNA repair
genes, DNA methyltransferase genes DNMT3B,264 members of the polycomb
complex EED,385 JAIRD2386 and polycomb target genes were detected as
differentially methylated. Specifically 230 CpG sites covering 158 polycomb target
genes previously characterized in embryonic fibroblasts387 presented as differentially
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methylated between IGHV mutated and unmutated CLL. Approximately half of the
sites presented with a higher methylation level in unmutated CLL, whereas the other
half were found to have a higher level within the mutated subgroup. Preferential
methylation of developmental polycomb target genes has been frequently recognised
in other forms of cancer.388,389 That said, the exact biological relevance of this finding
is largely unexplored in cancer. What is known is that tumor-specific targeting of de
novo methylation at these targets is pre-programmed by an established epigenetic
system namely H3K27me3 that normally has a role in marking embryonic genes for
repression. Unlike normal cells, the EZH2 polycomb complex maintaining
H3K27me3 recruits DNA methyltransferase to these sites in cancer cells.389
A focused search for genes formerly implicated in CLL, found a number of survival
related (TCF3,390 LEF1391), proliferation (CD80,392 CD86393) and apoptosis
(FAS)394and BCR signaling related genes (IBTK).395 Moreover, 12 differentially
methylated genes identified in Paper III were found to overlap to this present study
and were shown to be largely concordant in terms of methylation status. For example,
the preferential methylation of tumour suppressor genes ABI3364 in IGHV unmutated
and WISP3366 in IGHV mutated subgroups was re-confirmed. In support of Corcoran
et al,308 we found the CLL prognostic gene ZAP70,166 to be preferentially methylated
in IGHV mutated patients relative to unmutated cases. Furthermore, Corcoran et al,308
have shown that methylation of ZAP70 correlates well to ZAP70 expression.
Recently, methylation analysis of ZAP70 intron 1 by pyrosequencing has been shown
to be a robust method correlating to ZAP70 and CD38 expression, IGHV mutation
status, overall survival and time to treatment. Given the lack of sufficient
standardisation with current flow cytometry quantitation methods, quantification by
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pyrosequencing can provide an alternative mode of analysis.396 For the first time,
CLL prognostic genes LPL170,173 and CLLU1177,178,394 were noted to be differentially
methylated between IGHV mutated and unmutated CLL. More specifically, higher
DNA methylation within the gene body of CLLU1 and the transcription start site
TSS1500 and gene body region of LPL in IGHV mutated CLL relative to IGHV
unmutated patients was demonstrated. In recent times, expression of both LPL and
CLLU1 has been noted to be higher in IGHV unmutated patients compared to IGHV
mutated cases.177,178,267 In CLL, high expression of these genes is associated with
poor clinical outcome.170,173 In view of these observations, it is interesting to
speculate that perhaps DNA methylation of these genes may contribute to their
differential expression seen in CLL.
One of the enriched canonical pathways highlighted through IPA analysis was the
molecular mechanisms of cancer pathway. Within this IPA derived pathway, we
identified pathways previously implicated in CLL namely the NF-κB/TNFR1 and
TGF-ß pathways. Of particular interest is the TNF/NF-κB pathway. Here ten
members of this pathway were found to be differentially methylated. For instance, a
CLL autocrine growth factor TNF,397,398 TNFRSF8 (CD30), a receptor for thioredoxin
(Trx)399 a survival factor for CLL cells400,401 and two TNF receptor genes, TNFSF1A
and TNFRSF1B, recently shown to be redox-controlled by protein-disulfide
isomerase (PDI) in complex with thioredoxin-1 (Trx1), were found to be
differentially methylated in mutated and unmutated CLL. Although these findings are
interesting, relating the role of DNA methylation to the functionalities of such a
pathway in CLL is difficult. The variable incidence of multiple or single CpG sites
across genes at variable locations along different gene regions (gene body, TSS1500
98

etc) makes interpretation challenging. Sometimes multiple CpG sites across the same
gene at different regions will have variable methylation values. These challenges are
further complicated by the fact that the biologically relevant level of DNA
methylation needed to effect gene expression is currently unknown.
With the prospect of aberrant DNA methylation marks as candidate prognosticators,
it is essential that such marks be stable in terms of DNA methylation level. To date, a
limited number of studies exist documenting the stability of DNA methylation over
time. Of the few studies available variable results ensue. This is perhaps in part
reflective of the different diseases and nature of the cohort studied in these reports.
However, more pressing inconsistencies stem from the alternative techniques
employed and differences in the processing and interpretation of DNA methylation
data. For example, a report examining bladder cancer metachronous tumours from
two individuals, has shown DNA methylation to be relatively stable over time both
within the individual and between patients.329 In contrast, a study by Bjornsson et
al328 has identified inter-individual age variation and differences occurring over time
within individuals, that would otherwise be over-looked by group averaging of the
data. These changes were shown to be clustered within family members highlighting
the possibility that genetic background may effect DNA methylation changes.324,328
Nevertheless, a study of DNA methylation in 40 monozygotic twins found 35% of
twin couples to have a disconcordant level of total DNA methylation, particularly
those over the age of 28 years.330 In this instance, different environmental influences
and exposures were thought to play a role.
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In light of the above findings we dedicated the second part of the study to examine
DNA methylation over time in paired CLL diagnostic and follow-up patients. Based
on average DNA methylation values across the groups, this study for the first time
established that global DNA methylation is relatively stable over time. Both IGHV
mutated and unmutated patients incurred only a few, small recurrent changes over
time. Interestingly however, on analyzing the intra-individual changes a larger
difference in the number of non recurrent differentially methylated sites were noted
over time between IGHV mutated and unmutated cases, that would otherwise be
missed on group averaging of the data. More specifically, intra-individual analysis of
IGHV unmutated patients showed a large difference whereas intra-individual
investigation of IGHV mutated patients showed no significant difference in the
number of non-recurrent differentially methylated sites over time (Figure 4.4 A). That
said, in global terms, these non-reccurent changes in IGHV-umutated cases equated
to a very small overall global change (<1%), when taking into account the 485,000
sites available on the array. Nevertheless, it is interesting to speculate that perhaps
these findings are reflective of the more indolent and aggressive disease course
associated with IGHV mutated and unmutated patients respectively. Notably, global
DNA methylation within IGHV unmutated patients over time was relatively stable
despite the implementation of treatment between diagnosis and follow-up. Thus it
appears that DNA methylation of CLL cells is not largely effected by therapy, at least
not in respect to overall DNA methylation.
It is difficult to ascertain whether or not some of these non-recurrent DNA
methylation changes act as driver epi-mutations causing the expansion of the CLL
clone. A more likely explanation, given the lack of recurrent changes over time,
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indicates that the changes encountered merely act as passenger events arising from
the higher proliferative nature in the preexisting unmutated clone. Nevertheless, it is
interesting to speculate that perhaps these changes may contribute to CLL
leukemogenesis by contributing to overall epigenomic instability.

Figure 4.4. Box plot visualizing the difference in number of non recurrent differentially
methylated sites overtime within and between patient matched diagnostic and follow-up
IGHV mutated and IGHV unmutated CLL patients.

Resting PB CLL cells are known to communicate with a pro-survival
microenvironment in proliferation centers of the LN resulting in proliferation
(~1%/day) of the CLL clone.89 Recently, a higher expression of genes involved in
proliferation and active BCR signaling were shown in the LN relative to the blood of
patient-matched CLL samples.118 In light of the anti-correlation of DNA methylation
to gene expression, we hypothesized that DNA methylation may partake in the
mechanism of differential gene expression seen within the different compartments of
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CLL. Furthermore, in mind of the possibility of aberrant DNA methylation marks as
candidate prognostic markers, it is important to establish whether such marks are
stable over different sampling sites. Therefore, in the third part of the study, we
examined the DNA methylation profiles of patient-matched CLL cells derived from
the PB and LN, to acertain the influence of the microenvironment on CLL patient
DNA methylation profiles. This study for the first time found that global DNA
methylation is rather similar in patient matched PB and LN samples. Only few, small
recurrent changes were identified. Moreover, the number of non-recurrent changes
although relatively low in global terms (<1%), were found to vary in number across
the intra-individual PB and LN pairs. Therefore it seems that unlike gene expression,
DNA methylation in CLL cells is not heavily influenced by the microenvironment.

In sum, on a larger scale to Paper III, this study reconfirms IGHV mutated and IGHV
unmutated CLL to have differential methylation profiles. More specifically, CLL
prognostic genes, polycomb target genes, and key members of TGF-ß and NFκB/TNFR1 pathways were noted to be differentially methylated. Finally, global DNA
methylation was shown to be relatively stable over time and to be remarkably similar
in CLL cells derived form different anatomical CLL compartments.
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5: CONCLUSIONS

This thesis applied IGHV gene sequencing and high resolution SNP and DNA
methylation microarray techniques in order to interrogate genetic and methylation
events that may contribute to CLL leukemogenesis in diverse prognostic subgroups
and subsets of CLL.

5.1. Paper I
•

Within the Swedish population-based cohort studied, the geographic bias in
IGHV3-21 gene frequency previously identified in Sweden was validated, albeit
at a lower frequency than formerly reported in our hospital- based cohort study.

•

IGHV3-21 patients were shown to have an inferior outcome independently of
stereotypy. Hence, no prognostic value could be attributed to IGHV3-21
stereotypy status.

5.2: Paper II
•

Poor prognostic IGHV3-21 subset #2 patients commonly carried more genomic
aberrations and larger sized alterations compared to favourable prognostic
IGHV4-34 subset #4 patients. Thus, it appears that subset #2 patients are more
genomically complex relative to subset #4.
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•

IGHV4-34 subset #4 patients exclusively carried the favourable prognostic
del(13q) marker, whereas poor prognostic subset #2 patients carried a high
frequency of the poor prognostic del(11q) marker. Hence, these findings may in
part be reflective of the favourable prognosis seen in subset #4 and the adverse
outcome seen in subset #2 patients.

5.3. Paper III
•

Distinct differential methylation profiles were detected in three divergent
prognostic subsets of CLL, IGHV mutated, unmutated and IGHV3-21.
Differentially methylated genes, such as TSGs, were preferentially methylated in
the poor prognostic IGHV unmutated subgroup compared to the favourable
prognostic IGHV mutated CLL. Moreover, genes involved in cell proliferation
were specifically unmethylated in the poor prognostic IGHV unmutated and
IGHV3-21 subgroups. Hence, these findings suggest that the methylation status of
certain key cellular genes may contribute to CLL pathogenesis and the divergent
clinical outcome seen in certain CLL subsets.

•

Through the use of methyl inhibitor and histone deacetylation drugs, the reexpression of methylated TSGs (ABI3, VHL) was demonstrated. Hence the
reversible nature of DNA methylation was functionally established.
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5.4: Paper IV
•

On a larger scale to Paper III, this study reconfirmed that IGHV mutated and
IGHV unmutated CLL are characterized by differential methylation profiles.
Differentiallly methylated sites between these subgroups primarily presented
outside of CpG islands. Preferential DNA methylation of CpG sites within known
CLL prognostic genes CLLU1 and LPL was notably higher in IGHV mutated
cases relative to IGHV unmutated patients. Key members of TGF-ß and NFκB/TNFR1 pathways and large numbers of polycomb targets were also shown to
be differentially methylated between IGHV mutated and unmutated CLL.

•

Global DNA methylation in paired diagnostic and follow-up IGHV-UM (treated)
CLL and IGHV-M (untreated) CLL patients was deemed to be relatively stable
over time. Hence, this finding supports the notion that abberant DNA methylation
events are early events in CLL pathogensis.

•

DNA methylation changes in patient-matched peripheral blood and lymph node
samples were found to be relatively similar. Hence, it seems the differences in the
PB and LN micro-environment does not heavily influence the DNA methylation
profiles of CLL cells.

Taken together, these studies provide a greater insight into the genetic alterations and
DNA methylation events occurring in divergent CLL prognostic subgroups.
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